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Abstract:  
To study the antikinetoplastid 3-nitroimidazo[1,2-a]pyridine pharmacophore, a structure-activity 
relationship study was conducted through the synthesis of 26 original derivatives and their in vitro 
evaluation on both Leishmania spp and Trypanosoma brucei brucei. This SAR study showed that 
the antitrypanosomal pharmacophore was less restrictive than the antileishmanial one and 
highlighted positions 2, 6 and 8 of the imidazopyridine ring as key modulation points. None of the 
synthesized compounds allowed improvement in antileishmanial activity, compared to previous 
hit molecules in the series. Nevertheless, compound 8, the best antitrypanosomal molecule in this 
series (EC50 = 17 nM, SI = 2650 & E° = -0.6 V), was not only more active than all reference drugs 
and previous hit molecules in the series but also displayed improved aqueous solubility and better 
in vitro pharmacokinetic characteristics: good microsomal stability (T1/2 > 40 min), moderate 
albumin binding (77 %) and moderate permeability across the blood brain barrier according to a 
PAMPA assay. Moreover, both micronucleus and comet assays showed that nitroaromatic 
molecule 8 was not genotoxic in vitro. It was evidenced that bioactivation of molecule 8 was 
operated by T. b. brucei type 1 nitroreductase, in the same manner as fexinidazole. Finally, a mouse 
pharmacokinetic study showed that 8 displayed good systemic exposure after both single and 
repeated oral administrations at 100 mg/kg (NOAEL) and satisfying plasmatic half-life (T1/2 = 7.7 
h). Thus, molecule 8 appears as a good candidate for initiating a hit to lead drug discovery program. 
 
Keywords: Imidazo[1,2-a]pyridine; Nitroaromatic; Nitroreductases; Kinetoplastids; Redox 
potentials; SARs.  
1. Introduction  
Kinetoplastid diseases are vectorial parasitoses caused by flagellated blood protozoa and 
transmitted to their hosts by specific insect vectors. These diseases are found in developing 
countries in intertropical regions, especially where health facilities are inadequate [1]. They 
threaten nearly one billion people, causing an estimated 30 000 deaths annually [2]. The World 
Health Organization (WHO) thereby classifies them as Neglected Tropical Diseases (NTDs) [3]. 
These infectious diseases are caused by two parasitic genera: Leishmania spp. and Trypanosoma 
spp. The first is responsible for leishmaniasis (caused by several Leishmania species) which can 
evolve in different forms (visceral, cutaneous or cutaneomucous) [4].  
The second genus contains most of Trypanosoma species especially T. cruzi causing Chagas 
disease in South and Central America, and T. brucei spp. responsible for Human African 
Trypanosomiasis (HAT, or sleeping sickness) [5,6]. HAT is found in 36 countries throughout sub-
Saharan Africa. It is estimated that 70 million people would be at risk of contracting it [7]. Two 
subspecies, T. brucei gambiense (T.b.g.) and T. brucei rhodesiense (T.b.r.), are at the origin of 
different symptoms and two clinical forms: chronic disease for T.b.g. and acute disease for T.b.r. 
Following the bite of the blood sucking fly (tsetse fly or glossina), the parasite penetrates into the 
derma and disseminates into the whole organism. In a first step, blood and lymph are affected by 
the bloodstream form, and patients show headaches, anemia, joint pain and various organ damages 
occur. This stage is called hemolymphatic stage. Then, without treatment, the parasites are able to 
cross the blood brain barrier (BBB) and invade the central nervous system (stage 2, or nervous 
stage), causing various neurological changes such as sleeping disorders (responsible for the name 
of the disease), abnormal tone and mobility, ataxia, psychiatric disorders, seizures, coma and 
finally, death, as all kinetoplastid diseases are lethal if untreated [7,8]. Nervertheless, very few 
efficient, safe and affordable drugs are proposed to treat the infected populations. Regarding HAT, 
treatments are complex because they are stage and species dependent. For early stage HAT, 
suramin and pentamidine, molecules presenting severe side effects, must be given by injection (IV 
or IM) for a prolonged period against T.b.r. and T.b.g. infections, respectively. For the late-stage, 
melarsoprol is given in T.b.r. infections despite the high toxicity of this arsenic derivative (it can 
cause encephalopathies in 10% of cases). Against T.b.g. infections, the NECT (Nifurtimox 
Eflornithine Combination Therapy) is prescribed despite the genotoxic character of nifurtimox [9]. 
Since the end of 2018, a new safer nitroaromatic drug, fexinidazole, is available to treat HAT 
[10,11]. Concerning the new chemical entities that are clinically studied by the Drug for Neglected 
Disease initiative (DNDi), only acoziborole (benzoxaborole derivative) is in phase IIb/III against 
HAT [10]. This quite limited drug portfolio calls for the research of new molecules that could 
strengthen the therapeutic arsenal and reduce the risk of emergence of resistant parasites. 
Concerning fexinidazole, a 2-substituted-5-nitroimidazole derivative, it is a prodrug which is 
activated through the reduction of its nitro group by a NADH-specific type 1 nitroreductase (NTR), 
to generate electrophilic cytotoxic metabolites (nitroso and hydroxylamine derivatives) able to 
form covalent adducts with DNA and that are cytotoxic for the parasite [9,12]. Only one 
mitochondrial type 1 nitroreductase was identified in Trypanosoma brucei [13]. The particularity 
of nitroreductases is that they are absent in mammalian cells and then, constitute important targets 
for the development of new selective antiparasitic treatments. In this context, nitroaromatic 
compounds are key derivatives that have been and remain studied to fight against kinetoplastids, 
as  shown with the structures of nifurtimox, fexinidazole and DNDI-0690, a novel 4-nitroimidazole 
derivative that is clinically studied against visceral leishmaniasis [14] (Figure 1).  
 
 
Figure 1. Structures of nitroheterocyclic drug-compounds that are marketed or clinically studied 
against Trypanosoma brucei and Leishmania infections. 
 
Within the framework of our research program, focused on the development of original 
nitroheterocyclic antikinetoplastid molecules, we formerly reported a first antileishmanial hit 
compound in 8-halogeno-3-nitroimidazo[1,2-a]pyridine series (hit A, Figure 2) [15]. 
Pharmacomodulation studies at position 8 of the scaffold were conducted and showed that 
introducing a 4-chlorophenylthio moiety improved in vitro antikinetoplastid activity (hit B, Figure 
2) [16]. However, hit-molecule A displayed limited water solubility while hit B showed a poor 
mouse liver microsomal stability (T1/2 = 3 min), even if some probable sulfoxide and sulfone 
metabolites remained active. Thus, to improve hydrosolubility, microsomal stability and 
antikinetoplastid activity of this nitroheterocyclic series, we explored deeper the structure activity 
relationships by studying the influence of substituents at position 2 and 6 of the imidazo[1,2-
a]pyridine ring and comparing to the activities of hits A and B.  
 
Figure 2. Structures and biological profiles of previously identified antikinetoplastid hit-
compounds in 3-nitroimidazo[1,2-a]pyridine series [15–17].  
 
  
 Hit A Hit B 
EC50 L. donovani promastigotes (µM) 1.8 1.0 
EC50 L. donovani amastigotes (µM) 5.5 1.3 
EC50 L. infantum axenic amastigotes (µM) 4.4 1.7 
EC50 T. b. brucei trypomastigotes (µM) 2.9 1.3 
CC50 HepG2 (µM) >31 >100 
 
2. Results and discussion 
To evaluate if redox potentials had an influence on the bioactivation of this chemical series by 
parasitic NTRs, analogs of hit A bearing a methyl group (electron donating) or a trifluoromethyl 
group (electron withdrawing) at position 6 of the imidazo[1,2a]pyridine ring were synthesized. A 
bromine atom was not included in the pharmacomodulation study considering that we previously 
noted that molecules belonging to this series and bearing a bromine atom at position 6 showed the 
same level of antiparasitic activity as their chlorinated analogs, these latter presenting the 
advantage to show a better aqueous solubility. Thus, in parallel with the previously described 6-
chloro analogue 1c of hit A, new derivatives 2c and 3c were obtained through a 3-steps synthesis 




Scheme 1. Synthesis of compounds 1a-c to 3a-c.  
Reagents and conditions: (i) 1,3-Dichloroacetone 1.1 equiv, EtOH or DME, 80°C, 31% to 60%; 
(ii) HNO3 6 equiv, H2SO4, 0°C→RT, 51% to 85%; (iii) Sodium benzenesulfinate 3 equiv, DMSO, 
RT, 3 h, 57% to 89%.  
 
To study the influence of the substituent at position 2 of the imidazo[1,2-a]pyridine ring, the 
phenylsulfonylmethyl group encountered in the structures of hit A and B was modulated (Scheme 
2). First, a 2-unsubstituted derivative (4b) was obtained through a cyclocondensation reaction of 
2-amino-3-bromo-5-chloropyridine with chloroacetaldehyde, followed by a nitration reaction. 
Then, the 2-methyl-substituted derivative 5b was synthesized by dehalogenation of 1a followed 
by a nitration reaction of 5a at position 3. Finally, the 2-hydroxymethyl-derivative 6 was obtained 
by hydrolysis of 1b in the presence of copper sulfate in aqueous DMSO [20]. 
 
 
Scheme 2. Synthesis of compounds 4a-b, 5a-b and 6.  
Reagents and conditions: (i) Chloroacetaldehyde 1.5 equiv, NaHCO3 2 equiv, EtOH, 80 °C, 31%; 
(ii) HNO3 6 equiv, H2SO4, 0°C→RT, 78% to 93%; (iii) NaBH4 1 equiv, DMSO, RT, 63%; (iv) 
CuSO4 1 equiv, DMSO/H2O (7.5:2.5), 100 °C, 32%.  
 
In order to explore the role of the sulfone moiety, an original 2-phenylthiomethyl derivative 7 was 
prepared from 1b by a substitution reaction with sodium thiophenolate, formed in situ with NaH 
in DMSO at RT (Scheme 3), according to a protocol that we previously reported [21].  
 
 
Scheme 3. Synthesis of compound 7.  
Reagents and conditions: (i) Thiophenol 1 equiv, NaH 1.1 equiv, DMSO, N2, RT, 28%.  
 
Then, the phenyl ring of the phenylsulfonylmethyle moiety was replaced by a methyl, cyclohexyl 
or pyridin-3-yl group, using a previously described reaction [15] and leading to original derivatives 
8-10 respectively, according to Scheme 4.  
 
Scheme 4. Synthesis of compounds 8-10.  
Reagents and conditions: (i) Appropriate sulfonyl chloride 2 equiv, NaHCO3 2 equiv, Na2SO3 2 
equiv, EtOH/H2O (1:1), N2, 120 °C, MW, 22% to 47%.  
 
To complete SAR data and allow comparison with hit B, nine derivatives (11–19) bearing a 4-
chlorophenylthio moiety at position 8 were synthesized, applying a protocol that we previously 
reported in various nitroaromatic series with antiparasitic potential [22,23] (Scheme 5).  
 
 
R6 R2 R8 = -Br R8 = -S-Ph-Cl 
CH3 CH2-SO2-Ph (2c) (11) 
CF3 CH2-SO2-Ph (3c) (12) 
Cl H (4b) (13) 
Cl CH3 (5b) (14) 
Cl CH2OH (6) (15) 
Cl CH2-S-Ph (7) (16) 
Cl CH2-SO2-CH3 (8) (17) 
Cl CH2-SO2-Cyclohexyl (9) (18) 
Cl CH2-SO2-Pyridin-3-yl (10) (19) 
 
Scheme 5. Synthesis of compounds 11-19.  
Reagents and conditions: (i) 4-Chlorothiophenol 1 equiv, NaH 1 equiv, DMSO, N2, RT, 20% to 90%.  
 
Still by analogy with hit B, the influence of the heteroatom at position 8 was investigated deeper. 
First, the synthesis of 8-anilino derivatives via a Buchwald-Hartwig cross-coupling reaction was 
investigated (Scheme 6). The reaction conditions were studied by varying several parameters such 
as nature of base, nature and amount of catalyst and ligand, nature of solvent, and reaction 
temperature. Three derivatives bearing an aniline moiety at position 8 were synthesized (Scheme 
6) in moderate yields (42% to 52%). Then, a selenium analogue (23) of hit B was also prepared 
according to a previously described protocol [24], as presented in Scheme 6.  
 
 
Scheme 6. Synthesis of 8-anilino derivatives 20-22 and 8-phenylselanyl derivative 23. 
Reagents and conditions: (i) Appropriate aniline 1.2 equiv, Pd(OAc)2 0.08 equiv, rac-BINAP 0.15 
equiv, K2CO3 1.8 equiv, toluene, N2, 140 °C, MW, 42% to 52 %; (ii) Bis(4-
chlorophenyl)diselenide 0.5 equiv, NaBH4 2 equiv, PEG-400, N2, 60 °C, 9 %. 
 
Globally, ten molecules (analogues of hit A) bearing a bromine atom at position 8 of the 
imidazo[1,2-a]pyridine ring and 13 molecules (analogues of hit B) bearing a phenylthio, 
phenylamino or phenylselanyl group at the same position were evaluated in vitro. Their influence 
on cell viability (cytotoxic concentration 50% = CC50) was assessed on the HepG2 cell line, using 
doxorubicin as a positive control. In vitro antileishmanial activity (measured through effective 
concentration 50% = EC50) was also measured on both the promastigote and axenic amastigote 
form of L. donovani and L. infantum, respectively. In parallel, the in vitro antitrypanosomal 
activity (EC50) of these derivatives was determined on the trypomastigote blood stream form (BSF) 
of T. b. brucei. For all molecules, selectivity indices (SI) were calculated. Their antikinetoplastid 
activity was compared to previous hit molecules and to commercially available reference drugs 
amphotericin B, miltefosine, fexinidazole, suramine, eflornithine and nifurtimox. The results are 
summarized in Table 1. 
Table 1. In vitro evaluation of molecules 1c-23 on L. donovani promastigotes, L. infantum axenic 
amastigotes, T. b. brucei trypomastigotes (BSF) and on the human hepatocyte HepG2 cell line.  
 
 
Cell viability Activity 









EC50 L. infantum 




EC50 T. b. brucei 
BSF (µM) 
SI T. b. 
brucei 
1c -CH2-SO2-Ph -Cl -Br >15.6a 5.3 ± 0.3 >2.9 16.4 ± 0.2 >1 1.4 ± 0.4 >11.1 
2c -CH2-SO2-Ph -CH3 -Br >31.2a 5.6 ± 1.4 >5.6 >3.1 - 1.2 ± 0.5 >26 
3c -CH2-SO2-Ph -CF3 -Br >15.6a 6.2 ± 0.7 >2.5 >3.1 - 4.0 ± 2.7 >3.9 
4b -H -Cl -Br 16.2 9.3 ± 1.7 1.7 15.9 ± 0.7 1 0.4 ± 0.01 40.5 
5b -CH3 -Cl -Br >125a >12.5c - 32.1 ± 0.7 >3.9 >50c - 
6 -CH2-OH -Cl -Br >125a >12.5c - 46.3 ± 1.4 >5.4 >50c - 
7 -CH2-S-Ph -Cl -Br >31.2a >12.5c - 17.8 ± 0.8 >1.8 >50c - 
8 -CH2-SO2-CH3 -Cl -Br 45 5.7 ± 1.4 7.9 >25








-Cl -Br >62.5a 0.8 ± 0.3 >78 77.8 ± 0.8 >0.8 0.025 ± 0.005 2500 
11 -CH2-SO2-Ph -CH3 4-Cl-Ph-S- >62.5a 2.6 ± 0.4 >24 5.0 ± 0.3 12.5 1.8 ± 0.5 >34.7 
12 -CH2-SO2-Ph -CF3 4-Cl-Ph-S- >7.8a 1.9 ± 0.2 >4.1 - - 0.17 ± 0.02 >45.9 
13 -H -Cl 4-Cl-Ph-S- >7.8a 2.5 ± 0.2 >3.1 - - 0.085 ± 0.02 >92.8 
14 -CH3 -Cl 4-Cl-Ph-S- >7.8a >12.5c - - - - - 
15 -CH2-OH -Cl 4-Cl-Ph-S- >15.6a 4.0 ± 0.3 >3.9 7.9 ± 0.3 >2 >50 - 
16 -CH2-S-Ph -Cl 4-Cl-Ph-S- >15.6a 7.4 ± 0.4 >2.1 - - >50 - 




-Cl 4-Cl-Ph-S- >31.2a 1.9 ± 0.1 >16.4 1.6 ± 0.2 >19.5 1.5 ± 0.1 >20.8 
19 
-CH2-SO2-
Pyridin-3-yl -Cl 4-Cl-Ph-S- >31.2
a 0.5 ± 0.1 >62.4 0.8 ± 0.2 >39 1.2 ± 0.2 >26 
20 -CH2-SO2-Ph -Cl Ph-NH- >3.9a - - - - - - 
21 -CH2-SO2-Ph -Cl 4-Cl-Ph-NH- >3.9a - - - - - - 
22 -CH2-SO2-Ph -Cl 4-CH3O-Ph-NH- >3.9a - - - - - - 
23 -CH2-SO2-Ph -Cl 4-Cl-Ph-Se- >7.8a 0.7 ± 0.1 >11.1 0.9 ± 0.1 >8.7 0.3 ± 0.03 >26 
Ref. 1 Hit A molecule >31a 1.8 ± 0.8 >17.2 4.4 ± 0.8 >7.1 2.9 ± 0.5 >10.7 
Ref. 2 Hit B molecule >100 1.0 ± 0.3 >100 1.7 ± 0.3 >58.8 1.3 ± 0.1 >76.9 
Ref. 3 Doxorubicinb 0.2 ± 0.02 - - - - - - 
Ref. 4 Amphotericin Bd 8.8 ± 0.3 0.07 ± 0.01 125.7 0.06 ± 0.001 146.7 - - 
Ref. 5 Miltefosined 85 ± 8.8 3.1 ± 0.2 27.4 0.8 ± 0.2 106.3 - - 
Ref. 6 Fexinidazoled,e >200c 1.2 ± 0.2 >166.7 3.4 ± 0.8 >58.8 0.6 ± 0.2 >333 
Ref. 7 Suramine >100c - - - - 0.03 ± 0.009 >3333 
Ref. 8 Eflornithinee >100c - - - - 13.3 ± 2.1 >7.5 
Ref. 9 Nifurtimoxe 45.2 ± 1.3 - - - - 2.6 ± 0.8 17.4 
a The product could not be tested at higher concentrations due to a lack solubility in the culture medium 
b Doxorubicin was used as a cytotoxic reference drug 
c The EC50 or CC50 value was not reached at the highest tested concentration 
d Amphotericin B, Miltefosine and Fexinidazole were used as antileishmanial reference drugs 
e Fexinidazole, Suramin, Eflornithine and Nifurtimox were used as anti-Trypanosoma brucei reference drugs 
f SI = CC50 HepG2 / EC50 L. infantum 
g SI = CC50 HepG2 / EC50 T. brucei brucei 
Bold: New antitrypanosomal hit 
Out of the 23 tested molecules, 7 showed a poor aqueous solubility (< 10 µM) limiting their in 
vitro evaluation. Among them, 8-anilino-derivatives 20-22 were particularly insoluble in 
biological culture media, indicating that the aniline moiety should be avoided at position 8 of the 
antitrypanosomal scaffold. Regarding the effect on the cell viability of the HepG2 human cells, all 
molecules appeared as weakly cytotoxic (15.6 ≤ CC50 < 125 µM) in comparison with doxorubicin 
(CC50 = 0.2 µM).   
Then, 20 molecules were screened in vitro for their activity against L. donovani promastigotes and 
compared both to previous hit molecules and to amphotericin B, miltefosine and fexinidazole. 
Among them, only compounds 9, 10, 17, 18 and 19, bearing an alkyl- or pyridin-3-yl-
sulfonylmethyl group at position 2, showed both good EC50 values (0.5 ≤ EC50 ≤ 1.9 µM) and 
good selectivity indices (16 < SI < 78). This suggests that a sulfonyl group in position 2 is needed 
to reach a good antileishmanial activity level on L. donovani promastigotes. 
When considering the screening against L. infantum axenic amastigotes, out of the 5 molecules 
that were active on L. donovani promastigotes, only compounds 18 and 19 remained active (0.8 ≤ 
EC50 ≤ 1.6 µM) and selective (19.5 < SI < 39). These results confirmed that, in addition to a 
sulfonylmethyl substituent at position 2 of the imidazopyridine ring, antileishmanial activity was 
also favored when substituting position 8 by a thiophenol moiety. Unfortunately, compounds 18 
and 19 were then evaluated on the intramacrophage amastigote stage of L. donovani and were not 
active (EC50 > 10 µM). Consequently, hit B still remains the most active antileishmanial molecule 
in this chemical series.  
Regarding antitrypanosomal activity, molecules were tested on the blood stream form of T. b. 
brucei and compared to reference drugs fexinidazole, suramin, eflornithine and nifurtimox. Out of 
the 20 tested molecules, 8 displayed submicromolar activities (0.017 ≤ EC50 ≤ 0.5 µM), quite 
significantly better than the ones of hit A and B (EC50 = 2.9 and 1.3 µM respectively). Contrary to 
what was noted for antileishmanial activity, these 8 antitrypanosomal molecules are equally 
distributed between hit A (8-Br) and hit B (8-thiophenol) derivatives, showing that the 
antitrypanosomal pharmacophore is less restrictive than the antileishmanial pharmacophore. 
Among these submicromolar active molecules, 8, 9, 10, 12, 17 and 23 presented a sulfonylmethyl 
moiety at position 2 whereas molecules 4b and 13 were not substituted. Nevertheless, 4b was the 
most cytotoxic derivative in the series and 13 showed a poor aqueous solubility. Then, as with 
antileishmanial activity, the sulfonylmethyl moiety seems to play a favorable role toward 
antitrypanosomal activity. When looking at hit A derivatives, methyl-, cyclohexyl- and pyridin-3-
yl-sulfonylmethyl groups provided good to excellent activities (molecules 8-10), showing that the 
substituent of the sulfonylmethyl moiety is a key modulation zone. Thus, molecule 8 appeared as 
the most active (EC50 = 17 nM) and selective (SI = 2647) antitrypanosomal molecule in the series. 
It was a lot more active than hits A and B (EC50 = 2.9 and 1.3 µM respectively) but also more 
active than fexinidazole (EC50 = 0.6 µM), suramin (EC50 = 30 nM), eflornithine (EC50 =13.3 µM) 
and nifurtimox (EC50 =2.6 µM). The selenium containing analog 23 of hit B appeared a lot less 
soluble in aqueous biological media than hit B despite being 4 times more active. Because of the 
same lack of water solubility, the 6-trifluoromethylated analogue 12 of hit B appeared less 
promising than other derivatives. Nevertheless, the comparison of the close activities of 11 and 12 
toward hit B but also 2c and 3c toward 1c and hit A, permitted to conclude that the 
antitrypanosomal pharmacophore allows small electron-donating or electron-withdrawing 
substituents such as CH3, Cl, Br or CF3 at position 6. 
From antitrypanosomal hit-molecule 8, to deeper evaluate the influence of the sulfonylmethyl 
moiety, a 2-methylthiomethyl analog (24) was synthesized from substrate 1b, using sodium 
methanethiolate as reagent (Table 2). Partial oxidation of the sulfur atom of 24 using m-CPBA in 
dichloromethane led to the sulfoxide derivative 25 (Table 2). The activities of 24 and 25 were 
evaluated in vitro for their activity against T. b. brucei and for their effect on cell viability on the 
HepG 2 cell line (Table 2). Thioether derivative 24 showed limited water solubility and modest 
antitrypanosomal activity (EC50 = 2.2 µM) whereas sulfoxide derivative 25 was very active against 
T. b. brucei (EC50 = 20 nM) and displayed excellent selectivity index (SI = 2570). These results 
confirmed that position 2 was key to the antiparasitic activity and indicated that the 
antitrypanosomal pharmacophore included either a sulfone or a sulfoxide functional group at 
position 2 of the imidazopyridine ring. 
 
Table 2. Synthesis and biological activities of compounds 24 and 25. 
 
Compound 
T. brucei brucei BSF  
EC50 (µM) 
HepG2 CC50 (µM) SI T. b. brucei 
24 2.20 ± 0.24 >15.6a >7.1 
25 0.020 ± 0.006 51.4 ± 8.3 2570 
a The product could not be tested at higher concentrations due to a poor solubility in aqueous 
medium. 
Reagents and conditions: (i) CH3SNa 1 equiv, DMSO, RT, 52% (ii) mCPBA 1 equiv, CH2Cl2, 
0 °C, 36%. 
 
To assess the influence of the aforementioned modulations at position 2, 6 and 8 on the reduction 
potential of this nitroaromatic scaffold, an electrochemical study was conducted on several 3-
nitroimidazo[1,2-a]pyridine derivatives using cyclic voltammetry. Experimental reduction 
potentials (Figure 3) were compared to the ones of fexinidazole, nifurtimox, and hit A (for 8-Br-
derivatives) or hit B (for 8-phenylthio-derivatives). For all tested compounds, a reversible single 
electron reduction was observed and attested the formation of a nitro radical anion. The redox 
potentials were measured and the values were corrected versus Normal Hydrogen Electrode 
(NHE). These values ranged from -0.58 V to -0.79 V, in comparison with the ones of nifurtimox 
(E0 = -0.61 V) and fexinidazole (E0 = -0.83 V). There was almost no difference in redox potential 
values when comparing hit A with hit B analogues, bearing the same substituents at positions 2 
and 6: the electronic effect of the bromine atom or of the p-chlorothiophenol group at position 8 
were almost the same. Introducing an aniline moiety at position 8 of the imidazopyridine ring 
(molecule 20, E0 = -0.69 V) had the same effect toward the redox potential value as a phenyl 
moiety [17] but allowed to reach a lower E° value than with a p-chlorothiophenol moiety (hit B, 
E0 = -0.63 V).  Modifying the substituent at position 6 of the imidazopyridine ring had a strong 
influence toward the reducibility of the nitro group: 6-trifluoromethyl-derivatives (3c and 12) 
displayed high E0 values (-0.60 to -0.58 V) whereas 6-methyl-derivatives (2c and 11) presented 
the lowest E0 values (-0.76 V) among the derivatives presenting a phenylsulfonylmethyl side chain 
at position 2. There was also an important influence of the substituent at position 2 toward E0 
values. Switching from phenylsulfonylmethyl derivatives 1c or hit B (E0 values = -0.65 V and -
0.63 V) to their phenylthiomethyl analogues 7 or 16 provided molecules with lower E0 values (-
0.70 and -0.72 V respectively). This effect that was rather comparable to the one noted with the 
hydrogen atom when comparing 16 to 13 (E0 = -0.74 V). This decrease in E0 value was even more 
acute when introducing a methyl group at position 2 (molecule 14, E0 = -0.79 V). Finally, by 
comparing the E0 values of compounds 1c and 8, it appeared that replacing the 
phenylsulfonylmethyl group by a methylsulfonylmethyl one was responsible for a significant 
increase in the redox potential values from -0.65 to -0.60 V. Nevertheless, no correlation between 
redox potential values and antiparasitic EC50 values could be noted in the studied series. 
 
 
Figure 3. Redox potentials (E0) of Hit A (left) and Hit B (right) derivatives determined by cyclic 
voltammetry and given versus NHE. Conditions: selected compounds (10-3 mol.L-1) in non-
aqueous medium (DMSO + 0.1 mol.L-1 (n-Bu4N)[PF6]) on GC microdisk (r = 0.5 mm) at room 
temperature. Scan rate: 0.2 V.s-1.  
 
These molecules being probable substrates of parasitic nitroreductases, the mechanism of 
bioactivation of molecule 8 in the Trypanosoma cell was investigated by comparing the EC50 
values measured on a wild-type strain with the one measured on a NTR-overexpressing strain. 
This assay confirmed that, like for nifurtimox and for all previous hit molecules studied in 3-
nitroimidazopyridine series, molecule 8 was bioactivated by T. b. brucei type 1 NTR as the EC50 
value of 8 on the NTR-overexpressing strain was 4 times lower than on the wild-type strain.  
(Figure 4). Noticeably, compound 8 was almost thirty times more active on T. b. brucei wild-type 
strain than nifurtimox. 
 
Figure 4. Sensitivity of wild-type and NTR-overexpressing T. brucei BSF trypomastigotes strains 
toward hit molecule 8 and nifurtimox control. 
 
The 3-amino-analogue 26 of hit compound 8 was also synthesized and evaluated in vitro to confirm 
the essentiality of the nitro group for antikinetoplastid activity. Molecule 26 was prepared by 
reduction of 8 in the presence of iron powder in refluxing acetic acid (Table 3). As expected, 26 
did not show any antileishmanial activity and displayed a poor antitrypanosomal activity (EC50 = 
7.2 µM). These results are consistent with the hypothesis that these 3-nitroimidazo[1,2-a]pyridines 








Table 3. Synthesis and biological activities of compounds 26. 
 
Compound 
L. donovani  
promastigotes 
EC50 (µM) 
L. infantum axenic 
amastigotes 
 EC50 (µM) 





26 >12.5a >100a 7.2 ± 0.8 >125b 
a The EC50 or CC50 value was not reached at the highest tested concentration. 
b The product could not be tested at higher concentrations due to a poor solubility in aqueous medium. 
Reagents and conditions: (i) Fe0 powder 10 equiv, AcOH, reflux, 30 min, 40 %. 
 
The poor microsomal stability of hit molecules A and B was a limiting PK parameter for further 
development of the series (hit A T1/2 = 9 min and hit B T1/2 = 3 min; T1/2 of propranolol control = 
26 min), although some metabolites of hit B remained active in vitro against Leishmania spp [16]. 
For that reason, more polar, ionizable or less lipophilic pyridin-3-yl- or methyl-sulfonylmethyl-
derivatives 8, 10 and 17 of hit B and 1c were evaluated in vitro for their microsomal stability 
(Table 4). As expected, microsomal stability was greatly improved when changing the phenyl ring 
(1c, T1/2 = 12 min) with a pyridine one (10, T1/2 = 27 min) and even better with a methyl group (8, 
T1/2 > 40 min). Effectively, molecules 10 and 8 were less lipophilic and more water-soluble than 
compound 1c, but some microsomal N-oxidation can possibly be anticipated on the pyridine 
moiety of 10. Even if real, this improvement in microsomal stability was less concluding 
comparing hit B to 17, most probably because the sulfur atom of the thiophenol moiety remains 
actively oxidized by microsomes in 17.  Thus, positions 2 and 6 of the imidazopyridine ring 
appeared as essential modulation sites for increasing microsomal stability. Besides, the binding of 
molecule 8 to human albumin was logically much lower than all other derivatives as the two 
aromatic rings that substitute the imidazopyridine ring in hit B (thiophenol and 
phenylsulfonylmethyl moieties) were avoided, leading to a decarbonated scaffold with lower 
molecular weight. Reducing the binding to human albumin could be an important parameter to 
control so as to optimize future in vivo activity that can be restricted by insufficient distribution. 
 
Table 4. In vitro pharmacokinetic data of selected key compounds. 
      








12 3 27 >40 12 
 
 
Some important physicochemical parameters of hit molecule 8 were also calculated or measured 
(Table 5):  molecule 8 showed average lipophilicity (cLogP = 1.14) and was 20 times more soluble 
in water than hit B (thermodynamic solubility of 8 = 26 µM versus 1.4 µM for hit B) [16].  
The mutagenicity of many nitroheterocyclic molecules towards bacteria or parasites has been 
known for many years [25], the reduction of the nitro group being at the origin of this property. 
For fexinidazole, nitroreductase-dependent mutagenic activity was observed in the Ames test. 
However, its genotoxicity evaluation in the micronucleus assay was negative for the native 
molecule and its two metabolites [26]. This result suggests that the Ames test, the international 
reference test for measuring the mutagenicity of a molecule in vitro [27], is not suitable for the 
evaluation of nitroheterocyclic molecules. Indeed, since they undergo metabolic activation by 
Salmonella type 1 NTRs during the test, it appears difficult to extrapolate their genotoxicity profile 
to humans. Thus, to overcome the presence of bacterial nitroreductases expressed by the 
Salmonella strains used in the Ames test, a study of the genotoxicity of compound 8 was carried 
out using two complementary assays. First, a micronucleus test was conducted on the CHO-K1 
cell line, both with and without addition of the metabolizing S9 mixture (see supplementary 
material). Molecule 8 showed no significant increase in micronucleated cell rates for all the tested 
concentrations (0.01 mM to 0.5 mM), either in the absence or presence of S9 mix, indicating that 
molecule 8 does not exert cytogenetic effects in CHO cells in culture and does not produce 
metabolites with cytogenetic effects. Then a comet assay was carried out on the HepG2 cell line 
at 5, 10 and 20 µM, exposing cells with compound 8 for 2, 24 or 72 h and using methyl 
methanesulfonate as a positive control (supplementary material): the values of % DNA in tail were 
similar to the ones obtained in control cells. The negative results of these 2 assays are consistent 
with those obtained with previously studied hit molecules in the series and also with those of 
fexinidazole that is also devoid of mutagenic properties. 
Finally, an in vivo toxicity study of molecule 8 was carried out to determine its maximal tolerated 
dose. A group of 4 mice received a once daily repeated oral (intragastrical gavage) dose of 
molecule 8 at 100 mg/kg for 5 days, and a follow-up was performed. As no side effect was 
detected, the No Observed Adverse Event Level (NOAEL) in mice was set at 100 mg/kg/day. A 
post-mortem examination revealed no lesion on different organs (brain, lung, heart, liver and 
kidney). Thereafter, a pharmacokinetic analysis was performed to identify the behavior of 
molecule 8 after oral administration. The main pharmacokinetic parameters are presented in Table 
5. Compound 8 was orally absorbed and showed good systemic exposure. It displayed a long half-
time (7.7 h) and, with a Tmax of 5 h, a single daily administration could be considered for further 
experiments. A PAMPA BBB assay finally showed the possibility for molecule 8 to cross the 










Thermodynamic solubility (µM) 25.8 ± 0.6 
PAMPA blood-brain barrier permeability assay : Pe (nm/s) 84.2 ± 2.9 
CNS MPO score 5.8 
Cmax in mouse (ng/mL) 741 ± 580 
Tmax in mouse (h) 5.0 ± 5.2 
Plasma half-life in mouse (h) 7.7 ± 1.3 
AUC0-inf (ng.h/mL) 7060 ± 693 
Clearance (mL/h) 0.51 ± 0.05 
Micronucleus assay (@ 10, 50, 100 and 500 µM +/- S9mix) Negative 
Comet assay (@ 5, 10 and 20 µM for 2, 24 and 72 h) Negative 
a Weighted clogP was computed by Marvin® (ChemAxon) 
 
 
3. Conclusion  
This antikinetoplastid SAR study was conducted through the synthesis and evaluation of 26 
original imidazo[1,2-a]pyridine derivatives. Although most of these molecules displayed modest 
to good in vitro antileishmanial activity on the promastigote form of L. donovani, they were 
ineffective on the axenic amastigote form of L. infantum and/or the intramacrophage amastigote 
form of L. donovani. However, nine of these compounds showed submicromolar EC50 values on 
T. b. brucei bloodstream form and low cytotoxicities on the HepG2 cell line, including 3 molecules 
with a selectivity index ≥2500. In this series, positions 2 and 6 appeared as key positions for 
modulating the reduction potential of these nitroheterocycles while maintaining their 
antitrypanosomal activity. Position 2 also allowed to improve mouse liver microsomal stability, as 
illustrated by the best molecule in this series (8) bearing a methylsulfonylmethyl group instead of 
the phenylsulfonylmethyl group found in previous hit molecules A and B. Indeed, in addition to 
its very good in vitro activity on T. b. brucei BSF (better than the ones of all reference compounds), 
its in vitro microsomal stability was >40 min and therefore greatly increased in comparison with 
previous imidazopyridine hit molecules that we reported. Compound 8 also displayed increased 
water solubility, appeared BBB-permeable in a PAMPA assay and was shown to be bioactivated 
by type 1 parasitic NTR. Moreover, this derivative was not genotoxic, neither the micronucleus 
assay nor in the comet assay, which could represent a significant improvement over nitroaromatic 
antitypanosomal drugs like nifurtimox. In the mouse, molecule 8 was orally absorbed and well 
tolerated after repeated administrations of 100 mg/kg for 5 days. Its long plasma half-life (7.7 h) 
is encouraging and opens the way for a hit to lead program searching for novel antikinetoplastid 
drug candidates. 
 
4. Experimental section 
4.1. Organic synthesis and characterizations 
Commercial reagents were used as received without additional purification. Melting points were 
determined in open capillary tubes with a Büchi apparatus and are uncorrected. Elemental analysis 
and HRMS were carried out at the Spectropole, Faculté des Sciences et Techniques de Saint-
Jérôme, Marseille, France. NMR spectra were recorded on a Bruker ARX 200 spectrometer or a 
Bruker AV 250 spectrometer at the Faculté de Pharmacie de Marseille, or a BRUKER Avance III 
nanobay 400 spectrometer at the the Spectropole, Faculté des Sciences et Techniques de Saint-
Jérôme, Marseille, or on a Bruker UltraShield 300 MHz or a Bruker IconNMR 400 MHz 
spectrometer at the Laboratoire de Chimie de Coordination, Toulouse (1H-NMR: 200, 250, 300 or 
400 MHz, 13C-NMR: 50, 63, 75 or 100 MHz). NMR references were the following: 1H: CHCl3 δ 
= 7.26, DMSO-d6 δ = 2.50 and 
13C: CHCl3 δ = 76.9, DMSO-d6 δ = 39.5. Solvents were dried by 
conventional methods. The following adsorbent was used for column chromatography: silica gel 
60 (Merck, particle size 0.063–0.200 mm, 70–230 mesh ASTM). TLC was performed on 5 cm × 
10 cm aluminum plates coated with silica gel 60F-254 (Merck) in an appropriate eluent. 
Visualization was made with ultraviolet light (254 nm). HRMS spectra were recorded on QStar 
Elite (Applied Biosystems SCIEX) spectrometer. PEG was the matrix for HRMS. The 
experimental exact mass was given for the ion which has the maximum isotopic abundance. Purity 
of synthetized compounds was checked with LC-MS analyses which were realized at the Faculté 
de Pharmacie de Marseille with a Thermo Scientific Accela High Speed LC System® coupled with 
a single quadrupole mass spectrometer Thermo MSQ Plus®. The RP-HPLC column used is a 
Thermo Hypersil Gold® 50 × 2.1 mm (C18 bounded), with particles of 1.9 µm diameter. The 
volume of sample injected on the column was 1 µL. The chromatographic analysis, total duration 
of 8 min, is made with the gradient of following solvents: t = 0 min, water/methanol 50/50; 0 < t 
< 4 min, linear increase in the proportion of methanol to a ratio water/methanol 5/95; 4 < t < 6 
min, water/methanol 5/95; 6 < t < 7 min, linear decrease in the proportion of methanol to return to 
a ratio 50/50 water/methanol; 6 < t < 7 min, water/methanol 50/50. The water used was buffered 
with 5 mM ammonium acetate. The retention times (tR) of the molecules analyzed are indicated in 
min.  
Compounds 1a, 1b and 1c were prepared as previously described [17]. 
4.1.1. 8-Bromo-2-chloromethyl-6-methylimidazo[1,2-a]pyridine (2a) 
To a solution of 3-bromo-5-methylpyridin-2-amine (2 g, 10.1 mmol, 1 equiv.) in ethanol (100 mL), 
1,3-dichloroacetone (1.46 g, 11.8 mmol, 1.1 equiv.) was added. The reaction mixture was stirred 
and heated under reflux for 72 h. The solvent was then evaporated in vacuo. Compound 2a was 
obtained, after purification by chromatography on silica gel (eluent: cyclohexane–ethyl acetate 
6.5:3.5) and recrystallization from propan-2-ol as a beige solid in 31% yield (0.82 g). mp: 151 °C. 
1H NMR (300 MHz, CDCl3) δ: 2.31 (3H, s), 4.79 (2H, s), 7.33 (1H, d, J = 1.4 Hz), 7.63 (1H, s), 
7.84 (1H, t, J = 1.2 Hz). 13C NMR (100 MHz, CDCl3) δ: 18.0 (CH3), 39.7 (CH2), 111.0 (C), 112.53 
(CH), 122.9 (C), 123.0 (CH), 130.7 (CH), 142.4 (C), 143.9 (C). LC/MS ESI+ tR 1.77 min, (m/z) 
[M+H]+ 259.08/261.09/263.12. HRMS (+ESI): 260.9609 (M + H+). Calcd for C9H8BrClN2: 
260.9610. 
4.1.2. 8-Bromo-2-chloromethyl-6-methyl-3-nitroimidazo[1,2-a]pyridine (2b) 
To a solution of 8-bromo-2-chloromethyl-6-methylimidazo[1,2-a]pyridine 2a (0.8 g, 3.09 mmol, 
1 equiv.) in concentrated sulfuric acid (8 mL) cooled by an ice-water bath, nitric acid 65% (850 
µL, 18.5 mmol, 6 equiv.) was added. The reaction mixture was stirred for 1 h at room temperature. 
Then, the mixture was slowly poured into an ice-water mixture and the desired product 
precipitated. The beige solid was collected by filtration, dried under reduced pressure and 
recrystallized from propan-2-ol to give the expected product 2b in 85% yield (0.8 g). mp 179 °C. 
1H NMR (400 MHz, CDCl3) δ: 2.51 (3H, d, J = 0.8 Hz), 5.10 (2H, s), 7.79 (1H, d, J = 1.1 Hz), 
9.24–9.25 (1H, m). 13C NMR (100 MHz, DMSO-d6) δ: 17.6 (CH3), 31.1 (CH2), 110.8 (C), 125.4 
(CH), 126.1 (C), 128.0 (C), 136.5 (CH), 140.8 (C), 146.5 (C). LC/MS ESI+ tR 2.04 min, (m/z) 




To a solution of 8-bromo-2-chloromethyl-6-methyl-3-nitroimidazo[1,2-a]pyridine 2b (0.5 g, 1.64 
mmol, 1 equiv.) in dimethylsulfoxide (30 mL), sodium benzenesulfinate (0.81 g, 4.93 mmol, 3 
equiv.) was added. The reaction mixture was stirred for 3 h at room temperature. The reaction 
mixture was then slowly poured into an ice-water mixture, making the desired product precipitate. 
The pale yellow solid was collected by filtration, dried under reduced pressure and recrystallized 
from acetonitrile to give the expected product 2c in 89% yield (0.6 g). mp 202 °C. 1H NMR (200 
MHz, CDCl3) δ: 2.50 (3H, d, J = 0.8 Hz), 5.17 (2H, s), 7.52–7.57 (2H; m), 7.67 (1H, tt, J = 1.3 
and 7.4 Hz), 7.76 (1H, d, J = 1.5 Hz), 7.86–7.89 (2H, m), 9.19–9.20 (1H, m). 13C NMR (50 MHz, 
CDCl3) δ: 18.6 (CH3), 57.0 (CH2), 112.4 (C), 124.9 (CH), 128.0 (C), 128.7 (2CH), 129.3 (2CH), 
131.7 (C), 134.3 (CH), 136.1 (CH), 139.3 (C), 139.4 (C), 141.7 (C). LC/MS ESI+ tR 1.81 min, 
(m/z) [M+H]+ 409.90/411.89/412.98. HRMS (+ESI): 411.9750 (M + H+). Calcd for 
C15H12BrN3O4S: 411.9785. 
4.1.4. 8-Bromo-2-chloromethyl-6-(trifluoromethyl)imidazo[1,2-a]pyridine (3a) 
To a solution of 3-bromo-5-trifluoromethylpyridin-2-amine (1 g, 4.15 mmol, 1 equiv.) in 1,2-
dimethoxyethane (60 mL), 1,3-dichloroacetone (0.58 g, 4.56 mmol, 1.1 equiv.) was added. The 
reaction mixture was stirred and heated under reflux for 72 h. The solvent was then evaporated in 
vacuo and the product 3a was directly involved in the next synthesis step, without being isolated. 
1H NMR (200 MHz, CDCl3) δ: 5.55 (2H, s), 7.62–7.71 (1H, m), 7.84–7.95 (1H, m), 8.22–8.32 




To a solution of 8-bromo-2-chloromethyl-6-(trifluoromethyl)imidazo[1,2-a]pyridine 3a (1 g, 3.19 
mmol, 1 equiv.) in concentrated sulfuric acid (12 mL) cooled by an ice-water bath, nitric acid 65% 
(1 mL, 19.14 mmol, 6 equiv.) was added. The reaction mixture was stirred for 1 h at room 
temperature. Then, the mixture was slowly poured into an ice-water mixture with sodium 
carbonate and extracted three times with dichloromethane. The organic layer was washed three 
times with brine, dried over MgSO4, filtered and evaporated. The crude residue was purified by 
column chromatography on silica gel (eluent: dichloromethane) and compound 3b was isolated as 
a white solid in 51% yield (0.58 g). mp 143 °C. 1H NMR (200 MHz, CDCl3) δ: 5.11 (2H, s), 8.06 
(1H, d, J = 1.5 Hz), 9.75–9.77 (1H, m). 13C NMR (50 MHz, CDCl3) δ: 38.1 (CH2), 114.3 (C), 
121.6 (C, q, J = 35.5 Hz), 122.1 (C, q, J = 272.9 Hz), 125.6 (CH, q, J = 5.5 Hz), 129.1 (CH, d, J = 
2.6 Hz), 130.5 (C), 142.5 (C), 148.8 (C). LC/MS ESI+ tR 2.83 min, (m/z) [M+H]
+ 357.97/358.95. 
HRMS (+ESI): 357.9202 (M + H+). Calcd for C9H4BrClF3N3O2: 357.9200. 
4.1.6. 8-Bromo-3-nitro-2-(phenylsulfonylmethyl)-6-(trifluoromethyl)imidazo[1,2-
a]pyridine (3c) 
To a solution of 8-bromo-2-chloromethyl-3-nitro-6-(trifluoromethyl)imidazo[1,2-a]pyridine 3b 
(0.5 g, 1.4 mmol, 1 equiv.) in dimethylsulfoxide (40 mL), sodium benzenesulfinate (0.69 g, 4.18 
mmol, 3 equiv.) was added. The reaction mixture was stirred for 2 h at room temperature. Then, 
the mixture was slowly poured into an ice-water mixture and extracted three times with 
dichloromethane. The organic layer was washed five times with brine, dried over MgSO4, filtered 
and evaporated. The crude residue was recrystallized from acetonitrile to obtain the expected 
product 3c as a white solid in 57% yield (0.37 g). mp 210 °C. 1H NMR (200 MHz, CDCl3) δ: 5.20 
(2H, s), 7.55–7.62 (2H, m), 7.68–7.72 (1H, m), 7.88–7.93 (2H, m), 8.05–8.06 (1H, m), 9.74–9.75 
(1H, m). 13C NMR (50 MHz, CDCl3) δ: 56.6 (CH2), 114.1 (C), 121.5 (C, q, J = 35.5 Hz), 122.1 
(C, q, J = 273.4 Hz), 125.3 (CH, q, J = 5.4 Hz), 128.5 (2CH), 129.1 (CH, d, J = 2.5 Hz), 129.3 
(2CH), 132.5 (C), 134.4 (CH), 139.0 (C), 140.6 (C), 142.4 (C). LC/MS ESI+ tR 2.76 min, (m/z) 
[M+H]+ 463.74/465.78/468.23. HRMS (+ESI): 465.9499 (M + H+). Calcd for C15H9BrF3N3O4S: 
465.9502. 
4.1.7. 8-Bromo-6-chloroimidazo[1,2-a]pyridine (4a) 
To a solution of 3-bromo-5-chloropyridin-2-amine (10 g, 48.2 mmol, 1 equiv.) in ethanol (150 
mL), chloroacetaldehyde (6.69 g, 72.3 mmol, 1.5 equiv.) and sodium bicarbonate (6.86 g, 81.6 
mmol, 2 equiv.) were added. The reaction mixture was stirred and heated under reflux for 96 h. 
Then, the mixture was slowly poured into an ice-water mixture and extracted three times with 
dichloromethane. The organic layer was washed three times with brine, dried over MgSO4, filtered 
and evaporated. Compound 4a was obtained, after purification by chromatography on silica gel 
(eluent: dichloromethane) and recrystallization from propan-2-ol as a pale beige solid in 31% yield 
(3.48 g). mp: 131 °C. 1H NMR (300 MHz, DMSO-d6) δ: 7.68 (1H, d, J = 1.2 Hz), 7.74 (1H, d, J 
= 1.8 Hz), 8.05 (1H, d, J = 1.2 Hz), 8.90 (1H, d, J = 1.8 Hz). 13C NMR (75 MHz, DMSO-d6) δ: 
110.9 (C), 111.8 (C), 116.0 (CH), 118.3 (C), 124.8 (CH), 127.3 (CH), 134.4 (CH). LC/MS ESI+ 
tR 1.21 min, (m/z) [M+H]
+ 231.09/233.09/235.10. HRMS (+ESI): 232.9300 (M + H+). Calcd for 
C7H4BrClN2: 232.9297. 
 
4.1.8. 8-Bromo-6-chloro-3-nitroimidazo[1,2-a]pyridine (4b) 
To a solution of 8-bromo-6-chloroimidazo[1,2-a]pyridine 4a (0.5 g, 2.16 mmol, 1 equiv.) in 
concentrated sulfuric acid (5 mL) cooled by an ice-water bath, nitric acid 65% (500 µL, 13 mmol, 
6 equiv.) was added. The reaction mixture was stirred for 1 h at room temperature. Then, the 
mixture was slowly poured into an ice-water mixture with potassium carbonate and extracted three 
times with dichloromethane. The organic layer was washed three times with brine, dried over 
MgSO4, filtered and evaporated. Compound 4b was obtained, after purification by 
chromatography on silica gel (eluent: dichloromethane) and recrystallization from propan-2-ol as 
a beige solid in 93% yield (0.56 g). mp 145 °C. 1H NMR (400 MHz, CDCl3) δ: 7.90 (1H, d, J = 
1.8 Hz), 8.65 (1H, s), 9.46 (1H, d, J = 1.8 Hz). 13C NMR (100 MHz, CDCl3) δ: 113.4 (C), 124.3 
(CH), 125.0 (C), 130.2 (C), 133.4 (CH), 138.1 (CH), 148.0 (C). LC/MS ESI+ tR 1.42 min, (m/z) 
[M+H]+ 275.98/276.96/277.58. HRMS (+ESI): 277.9149 (M + H+). Calcd for C7H3BrClN3O2: 
277.9148. 
4.1.9. 8-Bromo-6-chloro-2-methylimidazo[1,2-a]pyridine (5a) 
To a solution of sodium borohydride (0.07 g, 1.79 mmol, 1 equiv.) in dimethylsulfoxide (60 mL), 
8-bromo-6-chloro-2-chloromethylimidazo[1,2-a]pyridine 1a (0.5 g, 1.79 mmol, 1 equiv.) was 
added. The reaction mixture was stirred for 72 h at room temperature. Then, the mixture was 
slowly poured into an ice-water mixture and extracted three times with dichloromethane. The 
organic layer was washed five times with brine, dried over MgSO4, filtered and evaporated. 
Compound 5a was obtained, after purification by chromatography on silica gel (eluent: 
dichloromethane/cyclohexane/diethyl ether 7:2.5:0.5) and recrystallization from acetonitrile as a 
white solid in 63% yield (0.28 g). mp 140 °C. 1H NMR (300 MHz, CDCl3) δ: 2.48 (3H, s), 7.39–
7.41 (2H, m), 8.70 (1H, d, J = 1.8 Hz). 13C NMR (75 MHz, CDCl3) δ: 14.7 (CH3), 111.1 (C), 112.0 
(CH), 119.5 (C), 122.5 (CH), 127.5 (CH), 141.8 (C), 145.5 (C). LC/MS ESI+ tR 1.71 min, (m/z) 
[M+H]+ 245.05/247.04/249.07. HRMS (+ESI): 246.9453 (M + H+). Calcd for C8H6BrClN2: 
246.9453. 
4.1.10. 8-Bromo-6-chloro-2-methyl-3-nitroimidazo[1,2-a]pyridine (5b) 
To a solution of 8-bromo-6-chloro-2-methylimidazo[1,2-a]pyridine 5a (0.3 g, 1.22 mmol, 1 
equiv.) in concentrated sulfuric acid (5 mL) cooled by an ice-water bath, nitric acid 65% (500 µL, 
7.3 mmol, 6 equiv.) was added. The reaction mixture was stirred for 30 min at room temperature. 
Then, the mixture was slowly poured into an ice-water mixture and the desired product 
precipitated. The yellow solid was collected by filtration, dried under reduced pressure and 
recrystallized from acetonitrile to give the expected product 5b in 78% yield (0.28 g). mp 192 °C. 
1H NMR (300 MHz, DMSO-d6) δ: 2.74 (3H, s), 8.36 (1H, d, J = 1.8 Hz), 9.34 (1H, d, J = 1.8 Hz). 
13C NMR (75 MHz, DMSO-d6) δ: 14.0 (CH3), 111.3 (C), 122.6 (C), 125.2 (CH), 131.2 (C), 133.5 
(CH), 140.7 (C), 150.1 (C). LC/MS ESI+ tR 2.13 min, (m/z) [M+H]
+ 289.90/291.90/293.90. HRMS 
(+ESI): 291.9302 (M + H+). Calcd for C8H5BrClN3O2: 291.9304. 
4.1.11. (8-Bromo-6-chloro-3-nitroimidazo[1,2-a]pyridin-2-yl)methanol (6) 
To a solution of copper sulfate pentahydrate (0.77 g, 3.08 mmol, 1 equiv.) in a 
dimethylsulfoxide/water mixture (7.5/2.5, 80 mL), 8-bromo-6-chloro-2-chloromethyl-3-
nitroimidazo[1,2-a]pyridine 1b (1 g, 3.08 mmol, 1 equiv.) was added. The reaction mixture was 
stirred and heated at 100 °C for 24 h. Then, the mixture was slowly poured into an ice-water 
mixture with sodium carbonate and extracted three times with dichloromethane. The organic layer 
was washed five times with brine, dried over MgSO4, filtered and evaporated. The crude residue 
was purified by column chromatography on silica gel (eluent: dichloromethane/ethyl acetate 
9.5:0.5) and compound 6 was isolated as a white solid in 32% yield (0.3 g). mp 202 °C. 1H NMR 
(300 MHz, DMSO-d6) δ: 4.92 (2H, d, J = 6.3 Hz), 5.57 (1H, t, J = 6.3 Hz), 8.38 (1H, d, J = 1.8 
Hz), 9.36 (1H, d, J = 1.8 Hz). 13C NMR (75 MHz, DMSO-d6) δ: 58.3 (CH2), 111.9 (C), 122.9 (C), 
125.2 (CH), 129.7 (C), 133.6 (CH), 141.0 (C), 153.2 (C). LC/MS ESI+ tR 1.01 min, (m/z) [M+H]
+ 
305.84/307.83/309.91. HRMS (+ESI): 307.9255 (M + H+). Calcd for C8H5BrClN3O3: 307.9253. 
 
4.1.12. 8-Bromo-6-chloro-3-nitro-2-(phenylthiomethyl)imidazo[1,2-a]pyridine (7) 
To a sealed 20 mL flask containing a solution of NaH 60% (0.07 g, 0.98 mmol, 1.1 equiv.) in 
dimethylsulfoxide (3 mL), thiophenol (0.17 g, 1.54 mmol, 1 equiv.) was added under N2 
atmosphere. The reaction mixture was stirred for 30 min at room temperature. Then, a solution of 
8-bromo-6-chloro-2-chloromethyl-3-nitroimidazo[1,2-a]pyridine 1b (0.5 g, 1.54 mmol, 1 equiv.) 
in dimethylsulfoxide was injected. The reaction mixture was stirred at room temperature for 45 
min. Then, the mixture was slowly poured into an ice-water mixture and extracted three times with 
dichloromethane. The organic layer was washed five times with brine, dried over MgSO4, filtered 
and evaporated. The crude residue was purified by column chromatography on silica gel (eluent: 
dichloromethane/cyclohexane 6:4) and compound 7 was isolated as a yellow solid in 28% yield 
(0.17 g). mp 136 °C. 1H NMR (250 MHz, CDCl3) δ: 4.66 (2H, s), 7.19–7.31 (3H, m), 7.45–7.48 
(2H, m), 7.86 (1H, d, J = 1.7 Hz), 9.46 (1H, d, J = 1.1 Hz). 13C NMR (62.5 MHz, CDCl3) δ: 33.4 
(CH2), 112.9 (C), 124.7 (C), 124.9 (CH), 127.3 (CH), 129.1 (2CH), 131.0 (2CH), 131.9 (C), 133.9 
(CH), 134.8 (C), 141.0 (C), 150.5 (C). LC/MS ESI+ tR 4.01 min, (m/z) [M+H]
+ 398.81/399.84. 
HRMS (+ESI): 399.9336 (M + H+). Calcd for C14H9BrClN3O2S: 399.9338. 
4.1.13. General procedure for the preparation of sulfone derivatives from the 8-
bromo-6-chloro-2-chloromethyl-3-nitroimidazo[1,2-a]pyridine (1b) : 
To a 20 mL flask containing a solution of 8-bromo-6-chloro-2-chloromethyl-3-nitroimidazo[1,2-
a]pyridine 1b (0.8 g, 2.46 mmol, 1 equiv.) in a water/ethanol mixture (1:1, 12 mL), sodium 
bicarbonate (0.42 g, 4.92 mmol, 2 equiv.), sodium sulfite (0.62 g, 4.92 mmol, 2 equiv.) and the 
appropriate sulfonyl chloride (4.92 mmol, 2 equiv.) were added. The flask was sealed and the 
mixture was heated at 120 °C under microwave irradiation until complete disappearance of the 
starting material (as monitored by LC/MS or TLC). Water was then added and the mixture was 
extracted three times with dichloromethane. The organic layer was dried over MgSO4, filtered and 
evaporated. The crude residue was purified by column chromatography on silica gel and 
recrystallized from the appropriate solvent, affording compounds 8 to 10. 
4.1.13.1. 8-Bromo-6-chloro-2-(methylsulfonylmethyl)-3-nitroimidazo[1,2-
a]pyridine (8) 
Compound 8 was obtained after purification by chromatography (eluent: dichloromethane/ethyl 
acetate 9:1) and recrystallization from propan-2-ol as a pale brown solid in 47% yield (0.43 g). mp 
233 °C. 1H NMR (400 MHz, CDCl3) δ: 3.20 (3H, t, J = 0.9 Hz), 5.09 (2H, q, J = 0.9 Hz), 7.96 
(1H, d, J = 1.8 Hz), 9.51 (1H, d, J = 1.8 Hz). 13C NMR (100 MHz, CDCl3) δ: 41.9 (CH3), 54.9 
(CH2), 113.3 (C), 125.0 (CH), 125.6 (C), 131.1 (C), 134.5 (CH), 140.3 (C), 141.3 (C). LC/MS 
ESI+ tR 0.86 min, (m/z) [M+H]
+ 367.76/369.89/370.94. HRMS (+ESI): 369.9077 (M + H+). Calcd 
for C9H7BrClN3O4S: 369.9079. 
4.1.13.2. 8-Bromo-6-chloro-2-(cyclohexylsulfonylmethyl)-3-nitroimidazo[1,2-
a]pyridine (9) 
Compound 9 was obtained after purification by chromatography (eluent: dichloromethane) and 
recrystallization from acetonitrile as a yellow solid in 29% yield (0.31 g). mp 214 °C. 1H NMR 
(400 MHz, CDCl3) δ: 1.22–1.40 (3H, m), 1.60–1.77 (3H, m), 1.96–2.01 (2H, m), 2.29–2.33 (2H, 
m), 3.28 (1H, tt, J = 3.4 and 12.2 Hz), 5.02 (2H, s), 7.92 (1H, d, J = 1.8 Hz), 9.47 (1H, d, J = 1.8 
Hz). 13C NMR (100 MHz, CDCl3) δ: 25.1 (2CH2), 25.2 (CH2), 25.3 (2CH2), 50.1 (CH2), 61.8 (CH), 
113.2 (C), 125.0 (CH), 125.4 (C), 127.0 (C), 134.3 (CH), 140.5 (C), 141.2 (C). LC/MS ESI+ tR 




Compound 10 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane/diethyl ether 5:3:2) and recrystallization from acetonitrile as a 
yellow solid in 21% yield (0.22 g). mp 220 °C. 1H NMR (400 MHz, CDCl3) δ: 5.21 (2H, s), 7.53–
7.56 (1H, m), 7.91 (1H, d, J = 1.8 Hz), 8.21 (1H, dt, J = 1.7 and 8.1 Hz), 8.90 (1H, bd, J = 3.9 Hz), 
9.01 (1H, bs), 9.45 (1H, d, J = 1.8 Hz). 13C NMR (100 MHz, CDCl3) δ: 56.9 (CH2), 113.4 (C), 
124.0 (CH), 124.9 (CH), 125.8 (C), 128.3 (C), 134.5 (CH), 135.8 (C), 136.9 (CH), 139.3 (C), 141.2 
(C), 149.7 (CH), 154.6 (CH). LC/MS ESI+ tR 1.21 min, (m/z) [M+H]
+ 430.61/432.29/433.31. 
HRMS (+ESI): 430.9210 (M + H+). Calcd for C13H8BrClN4O4S: 430.9211. 
4.1.14. General procedure for the preparation of 8-(4-chlorophenylthio)imidazo[1,2-
a]pyridine derivatives (11 to 19): 
To a sealed 20 mL flask containing NaH 60% (9.4 mg, 0.47 mmol, 1 equiv.) in dimethylsulfoxide 
(1 mL), 4-chlorothiophenol (68 mg, 0.47 mmol, 1 equiv.) was added under N2 atmosphere. The 
reaction mixture was stirred at room temperature for 30 min. Then a solution of the appropriate 8-
bromo-3-nitro-imidazo[1,2-a]pyridine derivative (0.47 mmol, 1 equiv.) in dimethylsulfoxide (5 
mL) was injected. The reaction mixture was stirred at room temperature until complete 
disappearance of the starting material (as monitored by LC/MS or TLC). The reaction mixture was 
then poured into an ice-water mixture. The mixture was extracted three times with 
dichloromethane, then the organic layer was washed five times with brine, dried over MgSO4, 
filtered and evaporated. The crude residue was purified by column chromatography on silica gel 
and/or recrystallized from the appropriate solvent, affording compounds 11 to 19. 
4.1.14.1. 8-[4-(Chlorophenyl)thio]-6-methyl-3-nitro-2-
(phenylsulfonylmethyl)imidazo[1,2-a]pyridine (11) 
Compound 11 was obtained after purification by chromatography (eluent: petroleum ether/ethyl 
acetate 7:3) and recrystallization from acetonitrile as a yellow solid in 90% yield (0.18 g). mp 184 
°C. 1H NMR (200 MHz, CDCl3) δ: 2.34 (3H, s), 5.17 (2H, s), 6.77 (1H, d, J = 1.1 Hz), 7.44–7.48 
(2H, m), 7.51–7.57 (4H, m), 7.64–7.70 (1H, m), 7.87–7.90 (2H, m), 8.96–8.97 (1H, m). 13C NMR 
(50 MHz, CDCl3) δ: 19.0 (CH3), 56.9 (CH2), 122.7 (C), 127.5 (C), 127.8 (CH), 128.7 (2CH), 129.2 
(C), 129.3 (2CH), 130.5 (CH), 130.6 (2CH), 131.1 (C), 134.2 (CH), 136.6 (C), 136.7 (2CH), 138.7 
(C), 139.4 (C), 141.0 (C). LC/MS ESI+ tR 3.80 min, (m/z) [M+H]
+ 473.83/475.84. HRMS (+ESI): 
474.0340 (M + H+). Calcd for C21H16ClN3O4S2: 474.0344. 
4.1.14.2. 8-[4-(Chlorophenyl)thio]-3-nitro-2-(phenylsulfonylmethyl)-6-
(trifluoromethyl)imidazo[1,2-a]pyridine (12) 
Compound 12 was obtained after recrystallization from propan-2-ol as a yellow solid in 70% yield 
(0.17 g). mp 191 °C. 1H NMR (250 MHz, CDCl3) δ: 5.18 (2H, s), 6.91 (1H, d, J = 1.2 Hz), 7.47–
7.63 (6H, m), 7.71 (1H, t, J = 7.4 Hz), 7.90 (2H, dd, J = 1.4 and 7.2 Hz), 9.44 (1H, s). 13C NMR 
(62.5 MHz, CDCl3) δ: 56.7 (CH2), 120.5 (CH, d, J = 2.7 Hz), 121.6 (C, q, J = 34.8 Hz), 122.5 (CH, 
d, J = 5.6 Hz), 122.5 (C, q, J = 272.8 Hz), 125.6 (CH), 128.6 (2CH), 129.4 (2CH), 131.0 (C), 132.0 
(2CH), 134.0 (C), 134.5 (C), 137.1 (2CH), 137.6 (C), 139.2 (C), 139.9 (C), 141.4 (C). LC/MS 
ESI+ tR 4.24 min, (m/z) [M+H]
+ 528.11/529.15. HRMS (+ESI): 528.0061 (M + H+). Calcd for 
C21H13ClF3N3O4S2: 528.0061. 
4.1.14.3. 6-Chloro-8-[4-(chlorophenyl)thio]-3-nitroimidazo[1,2-a]pyridine (13) 
Compound 13 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane 7:3) and recrystallization from acetonitrile as a yellow solid in 69% 
yield (0.11 g). mp 192 °C. 1H NMR (400 MHz, CDCl3) δ: 6.78 (1H, d, J = 1.8 Hz), 7.49–7.53 (2H, 
m), 7.57–7.60 (2H, m), 8.59 (1H, s), 9.20 (1H, d, J = 1.8 Hz). 13C NMR (100 MHz, CDCl3) δ: 
121.6 (CH), 125.7 (CH), 125.8 (C), 126.2 (C), 130.9 (2CH), 133.0 (C), 133.3 (C), 137.0 (2CH), 
137.4 (C), 137.5 (CH), 142.1 (C). LC/MS ESI+ tR 4.10 min, (m/z) [M+H]
+ 340.10/341.11/342.08. 
HRMS (+ESI): 339.9705 (M + H+). Calcd for C13H7Cl2N3O2S: 339.9709. 
4.1.14.4. 6-Chloro-8-[4-(chlorophenyl)thio]-2-methyl-3-nitroimidazo[1,2-
a]pyridine (14) 
Compound 14 was obtained after purification by chromatography (eluent: dichloromethane) and 
recrystallization from acetonitrile as a yellow solid in 75% yield (0.13 g). mp 199 °C. 1H NMR 
(400 MHz, CDCl3) δ: 2.89 (3H, s), 6.75 (1H, d, J = 1.8 Hz), 7.48–7.60 (4H, m), 9.23 (1H, d, J = 
1.8 Hz). 13C NMR (100 MHz, CDCl3) δ: 17.5 (CH3), 122.2 (CH), 124.8 (C), 125.9 (CH), 126.4 
(C), 130.9 (2CH), 131.2 (C), 131.6 (C), 137.0 (2CH), 137.3 (C), 140.0 (C), 150.5 (C). LC/MS 
ESI+ tR 4.50 min, (m/z) [M+H]
+ 354.08/355.19/356.31. HRMS (+ESI): 353.9864 (M + H+). Calcd 
for C14H9Cl2N3O2S: 353.9865. 
4.1.14.5. {6-Chloro-8-[4-(chlorophenyl)thio]-3-nitroimidazo[1,2-a]pyridin-2-
yl}methanol (15) 
Compound 15 was obtained after purification by chromatography (eluent: 
dichloromethane/methanol 9.8:0.2) as a pale yellow solid in 40% yield (70 mg). mp 227 °C. 1H 
NMR (400 MHz, DMSO-d6) δ: 4.92 (2H, s), 5.54 (1H, sl), 6.99 (1H, d, J = 1.8 Hz), 7.61–7.68 
(4H, m), 9.17 (1H, d, J = 1.8 Hz). 13C NMR (100 MHz, DMSO-d6) δ: 58.2 (CH2), 122.9 (CH), 
123.3 (C), 126.6 (CH), 127.2 (C), 129.4 (C), 129.7 (C), 130.5 (2CH), 135.1 (C), 136.2 (2CH), 
140.0 (C), 152.5 (C). LC/MS ESI+ tR 3.68 min, (m/z) [M+H]
+ 369.86/371.12/372.06. HRMS 
(+ESI): 369.9811 (M + H+). Calcd for C14H9Cl2N3O3S: 369.9814. 
4.1.14.6. 6-Chloro-8-[4-(chlorophenyl)thio]-3-nitro-2-
(phenylthiomethyl)imidazo[1,2-a]pyridine (16) 
Compound 16 was obtained after purification by chromatography (eluent: petroleum 
ether/dichloromethane 5.5:4.5) as a yellow solid in 21% yield (46 mg). mp 142 °C. 1H NMR (200 
MHz, CDCl3) δ: 4.67 (2H, s), 6.76 (1H, d, J = 1.8 Hz), 7.22–7.25 (1H, m), 7.29–7.33 (1H, m), 
7.48–7.58 (7H, m), 9.21 (1H, d, J = 1.8 Hz). 13C NMR (50 MHz, CDCl3) δ: 33.3 (CH2), 122.1 (C), 
125.4 (C), 126.2 (CH), 126.3 (C), 127.1 (CH), 129.1 (2CH), 130.6 (2CH), 130.9 (2CH), 132.3 (C), 
135.2 (C), 135.9 (CH), 137.0 (2CH), 137.3 (C), 139.8 (C), 149.6 (C). LC/MS ESI+ tR 5.36 min, 





Compound 17 was obtained after purification by chromatography (eluent: dichloromethane) and 
recrystallization from acetonitrile as a beige solid in 46% yield (93 mg). mp 213 °C. 1H NMR (400 
MHz, DMSO-d6) δ: 3.07 (3H, s), 5.11 (2H, q, J = 0.8 Hz), 7.18 (1H, d, J = 1.8 Hz), 7.58–7.67 (4H, 
m), 9.22 (1H, d, J = 1.8 Hz). 13C NMR (100 MHz, DMSO-d6) δ: 40.9 (CH3), 54.1 (CH2), 123.5 
(CH), 123.9 (C), 127.5 (C), 128.0 (CH), 129.3 (C), 130.3 (2CH), 131.5 (C), 134.9 (C), 135.7 
(2CH), 139.4 (C), 140.0 (C). LC/MS ESI+ tR 3.42 min, (m/z) [M+H]
+ 432.70/433.72/434.89. 
HRMS (+ESI): 431.9640 (M + H+). Calcd for C15H11Cl2N3O4S2: 431.9641. 
4.1.14.8. 6-Chloro-8-[4-(chlorophenyl)thio]-2-(cyclohexylsulfonylmethyl)-3-
nitroimidazo[1,2-a]pyridine (18) 
Compound 18 was obtained after purification by chromatography (eluent: dichloromethane) and 
recrystallization from cyclohexane as a brown solid in 47% yield (0.11 g). mp 82 °C. 1H NMR 
(400 MHz, CDCl3) δ: 1.21–1.39 (3H, m), 1.61–1.78 (3H, m), 1.97–2.01 (2H, m), 2.31–2.34 (2H, 
m), 3.31 (1H, tt, J = 3.4 and 12.1 Hz), 5.02 (2H, s), 6.79 (1H, d, J = 1.8 Hz), 7.50–7.59 (4H, m), 
9.22 (1H, d, J = 1.8 Hz). 13C NMR (100 MHz, CDCl3) δ: 25.1 (2CH2), 25.2 (CH2), 25.3 (2CH2), 
50.0 (CH2), 61.6 (CH), 113.1 (C), 122.0 (CH), 126.0 (C), 126.3 (CH), 130.1 (C), 131.0 (2CH), 
132.8 (C), 137.0 (2CH), 137.5 (C), 139.5 (C), 140.0 (C). LC/MS ESI+ tR 4.57 min, (m/z) [M+H]
+ 
499.81/501.85/503.88. HRMS (+ESI): 500.0271 (M + H+). Calcd for C20H19Cl2N3O4S2: 500.0267. 
4.1.14.9. 6-Chloro-8-[4-(chlorophenyl)thio]-3-nitro-2-(pyridin-3-
ylsulfonylmethyl)imidazo[1,2-a]pyridine (19) 
Compound 19 was obtained after purification by chromatography (eluent: dichloromethane) and 
recrystallization from acetonitrile as a yellow solid in 20% yield (47 mg). mp 176 °C. 1H NMR 
(400 MHz, CDCl3) δ: 5.21 (2H, s), 6.74 (1H, d, J = 1.7 Hz), 7.50–7.59 (5H, m), 8.23 (1H, dt, J = 
1.7 and 7.9 Hz), 8.91 (1H, d, J = 4.1 Hz), 9.01 (1H, s), 9.17 (1H, d, J = 1.7 Hz). 13C NMR (100 
MHz, CDCl3) δ: 56.9 (CH2), 121.8 (CH), 123.9 (CH), 125.6 (C), 126.1 (CH), 126.4 (C), 131.0 
(2CH), 132.0 (C), 133.4 (C), 135.8 (C), 136.8 (CH), 137.2 (2CH), 137.6 (C), 138.4 (C), 139.9 (C), 
149.8 (CH), 154.8 (CH). LC/MS ESI+ tR 3.63 min, (m/z) [M+H]
+ 494.77/496.71. HRMS (+ESI): 
494.9750 (M + H+). Calcd for C19H12Cl2N4O4S2: 494.9750. 
4.1.15. General procedure for the preparation of 8-arylamino-imidazo[1,2-
a]pyridine derivatives (20 to 22): 
A mixture of 8-bromo-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridine 1c (400 
mg, 0.93 mmol, 1 equiv.), palladium diacetate (17 mg, 0.07 mmol, 0.08 equiv.), potassium 
carbonate (0.23 g, 1.7 mmol, 1.8 equiv.), rac-BINAP (87 mg, 0.14 mmol, 0.15 equiv.) and 
appropriate aniline (1.1 mmol, 1.2 equiv.) in toluene (12 mL) under N2 atmosphere was heated at 
140 °C under microwave irradiation until complete disappearance of the starting material (as 
monitored by LC/MS or TLC). Water was then added and the mixture was extracted three times 
with dichloromethane. The organic layer was washed three times with water, dried over MgSO4, 
filtered and evaporated. The crude residue was purified by column chromatography on silica gel 




Compound 20 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane 7:3) and recrystallization from propan-2-ol as an orange solid in 
50% yield (0.21 g). mp 254 °C. 1H NMR (400 MHz, CDCl3) δ: 5.18 (2H, s), 7.12–7.16 (2H, m), 
7.40–7.42 (4H, m), 7.60–7.64 (2H, m), 7.74–7.80 (3H, m), 8.72 (1H, d, J = 1.3 Hz), 9.09 (1H, bs). 
13C NMR (100 MHz, CDCl3) δ: 56.4 (CH2), 107.6 (CH), 114.6 (CH), 121.9 (2CH), 124.0 (CH), 
125.6 (C), 128.0 (2CH), 129.4 (4CH), 131.5 (C), 134.3 (CH), 134.5 (C), 136.3 (C), 136.9 (C), 
138.8 (C), 139.4 (C). LC/MS ESI+ tR 4.08 min, (m/z) [M+H]
+ 442.91/444.90. HRMS (+ESI): 
443.0577 (M + H+). Calcd for C20H15ClN4O4S: 443.0575. 
4.1.15.2. 6-Chloro-N-(4-chlorophenyl)-3-nitro-2-
(phenylsulfonylmethyl)imidazo[1,2-a]pyridin-8-amine (21) 
Compound 21 was obtained after purification by chromatography (eluent: dichloromethane) and 
recrystallization from propan-2-ol as an orange solid in 52% yield (0.23 g). mp 255 °C. 1H NMR 
(400 MHz, DMSO-d6) δ: δ 5.17 (2H, s), 7.18–7.20 (1H, m), 7.39–7.48 (4H, m), 7.59–7.63 (2H, 
m), 7.74–7.79 (3H, m), 7.76–7.76 (1H, m), 9.23 (1H, bs). 13C NMR (100 MHz, DMSO-d6) δ: 56.4 
(CH2), 108.5 (CH), 115.2 (CH), 123.1 (2CH), 125.5 (C), 127.3 (C), 128.0 (2CH), 129.3 (2CH), 
129.4 (2CH), 130.6 (C), 131.5 (C), 134.0 (C), 134.3 (CH), 137.0 (C), 138.7 (C), 138.8 (C). LC/MS 
ESI+ tR 4.99 min, (m/z) [M+H]




Compound 22 was obtained after purification by chromatography (eluent: 
dichloromethane/cyclohexane 9:1) and recrystallization from propan-2-ol as a red solid in 42% 
yield (0.19 g). mp 228 °C. 1H NMR (400 MHz, CDCl3) δ: 3.78 (3H, s), 5.17 (2H, s), 6.81 (1H, d, 
J = 1.4 Hz), 6.99–7.01 (2H, m), 7.30–7.32 (2H, m), 7.60–7.64 (2H, m), 7.74–7.80 (3H, m), 8.64 
(1H, d, J = 1.4 Hz), 8.93 (1H, s). 13C NMR (100 MHz, CDCl3) δ: 55.3 (CH3), 56.4 (CH2), 106.0 
(CH), 113.6 (CH), 114.7 (2CH), 125.0 (2CH), 125.8 (C), 128.0 (2CH), 129.4 (2CH), 131.4 (C), 
131.7 (C), 134.3 (CH), 135.9 (C), 136.0 (C), 136.8 (C), 138.8 (C), 156.5 (C). LC/MS ESI+ tR 4.62 




To a solution of 1,2-bis(4-chlorophenyl)diselenide [24] (0.4 g, 1.05 mmol, 1 equiv.) in PEG-400 
(4 mL) under N2 atmosphere, sodium borohydride (0.16 g, 4.2 mmol, 4 equiv.) was added. The 
reaction mixture was stirred 1 h at 60 °C. 8-bromo-6-chloro-3-nitro-2-
(phenylsulfonylmethyl)imidazo[1,2-a]pyridine 1c (0.9 g, 2.1 mmol, 2 equiv.) was then introduced. 
The resulting mixture was diluted with H2O and acidified with 1 N hydrochloric acid. The mixture 
was extracted three times with dichloromethane, dried over MgSO4, filtered and evaporated. The 
crude residue was purified by column chromatography on silica gel (eluent: dichloromethane) as 
a yellow solid in 9% yield (0.11 g). mp 209 °C. 1H NMR (250 MHz, CDCl3) δ: 5.15 (2H, s), 6.87 
(1H, d, J = 1.7 Hz), 7.42-7.75 (7H, m), 7.90 (2H, d, J = 7.3 Hz), 9.20 (1H, d, J = 1.7 Hz). 13C NMR 
(63 MHz, CDCl3) δ: 56.7 (CH2), 122.2 (CH), 122.5 (C), 126.3 (C), 128.6 (C), 128.7 (2CH), 128.9 
(C), 129.4 (2CH), 131.0 (2CH), 131.3 (CH), 134.4 (C), 137.3 (CH), 138.6 (2CH), 139.1 (C), 139.3 
(C), 140.7 (C). LC/MS ESI+ tR 4.31 min, (m/z) [M+H]
+ 541.68/543.53/546.10. HRMS (+ESI): 
540.9169 (M + H+). Calcd for C20H13Cl2N3O4SSe: 540.9171. 
4.1.17. 8-Bromo-6-chloro-2-(methylthiomethyl)-3-nitroimidazo[1,2-a]pyridine (24) 
To a solution of 8-bromo-6-chloro-2-chloromethyl-3-nitroimidazo[1,2-a]pyridine 1b (0.8 g, 2.46 
mmol, 1 equiv.) in DMSO (10 mL), a solution of sodium thiomethoxide (0.17 g, 2.46 mmol, 1 
equiv.) in DMSO (5 mL) was added dropwise. The reaction mixture was stirred for 45 min at room 
temperature. Then, the mixture was slowly poured into an ice-water mixture and the desired 
product precipitated. The yellow solid was collected by filtration, dried under reduced pressure 
and purified by column chromatography on silica gel (eluent: dichloromethane/cyclohexane 5:5) 
as a pale yellow solid in 52% yield (0.43 g). mp 186 °C. 1H NMR (400 MHz, DMSO-d6) δ: 2.13 
(3H, s), 4.13 (2H, s), 8.40 (1H, d, J = 1.8 Hz), 9.37 (1H, d, J = 1.8 Hz). 13C NMR (100 MHz, 
DMSO-d6) δ: 14.9 (CH3), 31.1 (CH2), 111.7 (C), 123.0 (CH), 125.5 (C), 130.0 (C), 133.8 (CH), 
140.7 (C), 150.4 (C). LC/MS ESI+ tR 2.76 min, (m/z) [M+H]
+ 334.64/337.82/339.91. HRMS 
(+ESI): 337.9182 (M + H+). Calcd for C9H7BrClN3O2S: 337.9181. 
4.1.18. 8-Bromo-6-chloro-2-(methylsulfinylmethyl)-3-nitroimidazo[1,2-a]pyridine 
(25) 
To a solution of 8-bromo-6-chloro-2-(methylthiomethyl)-3-nitroimidazo[1,2-a]pyridine 24 (0.4 g, 
1.19 mmol, 1 equiv.) in dichloromethane (40 mL) cooled by an ice-water bath, mCPBA (~70%) 
(0.29 g, 1.19 mmol, 1 equiv.) was added. The reaction mixture was stirred for 1 h at 0 °C. Then, 
the mixture was washed three times with H2O, dried over MgSO4, filtered and evaporated. The 
crude residue was purified by column chromatography on silica gel (eluent: dichloromethane/ethyl 
acetate 8:2) as a yellow solid in 36% yield (0.15 g). mp 164 °C. 1H NMR (400 MHz, DMSO-d6) 
δ: 2.70 (3H, s), 4.55-4.81 (2H, m), 8.42 (1H, d, J = 1.8 Hz), 9.38 (1H, d, J = 1.8 Hz). 13C NMR 
(100 MHz, DMSO-d6) δ: 38.6 (CH3), 53.3 (CH2), 111.8 (C), 123.3 (CH), 125.4 (C), 132.0 (C), 
134.0 (CH), 141.0 (C), 142.7 (C). LC/MS ESI+ tR 0.84 min, (m/z) [M+H]
+ 351.83/353.92/355.94. 
HRMS (+ESI): 353.9127 (M + H+). Calcd for C9H7BrClN3O3S: 353.9130. 
4.1.19. 8-Bromo-6-chloro-2-(methylsulfonylmethyl)imidazo[1,2-a]pyridin-3-amine 
(26) 
To a solution of 8-bromo-6-chloro-2-(methylsulfonylmethyl)-3-nitroimidazo[1,2-a]pyridine 8 
(0.2 g, 0.54 mmol, 1 equiv.) in acetic acid (30 mL), iron powder (0.3 g, 5.4 mmol, 10 equiv.) was 
added. The reaction mixture was stirred and heated under reflux for 30 min. The mixture was then 
filtered through celite and the solvent was removed in vacuo. The resulting residue was diluted 
with H2O and basified with sat. aq. NaHCO3. The mixture was extracted three times with 
dichloromethane, dried over MgSO4, filtered and evaporated. The crude residue was purified by 
column chromatography on silica gel (eluent: dichloromethane/diethyl ether 6:4) as a yellow solid 
in 40% yield (0.07 g). mp 215 °C. 1H NMR (250 MHz, DMSO) δ: 3.02 (3H, s), 4.62 (2H, s), 5.62 
(2H, s), 7.50 (1H, d, J = 1.7 Hz), 8.33 (1H, d, J = 1.7 Hz). 13C NMR (62.5 MHz, DMSO) δ: 40.1 
(CH3), 52.7 (CH2), 110.8 (C), 117.4 (CH), 117.6 (C), 119.9 (C), 123.7 (CH), 133.0 (C), 134.2 (C). 
LC/MS ESI+ tR 1.03 min, (m/z) [M+H]
+ 337.90/339.92/341.95. HRMS (+ESI): 339.9336 (M + 
H+). Calcd for C9H9N3O2SBrCl: 339.9337. 
 
4.2. Electrochemistry 
Voltammetric measurements were carried out with a potentiostat Autolab PGSTAT100 (ECO 
Chemie, The Netherlands) controlled by GPES 4.09 software. Experiments were performed at 
room temperature in a homemade airtight three–electrode cell connected to a vacuum/argon line. 
The reference electrode consisted of a saturated calomel electrode (SCE) separated from the 
solution by a bridge compartment. The counter electrode was a platinum wire of 1 cm² apparent 
surface. The working electrode was GC microdisk (1.0 mm of diameter – Bio-logic SAS). The 
supporting electrolyte (nBu4N)[PF6] (Fluka, 99% puriss electrochemical grade) and the solvent 
DMSO (Sigma-Aldrich puriss p.a. dried <0.02% water) were used as received and simply degassed 
under argon. The solutions used during the electrochemical studies were typically 10-3 M in 
compound and 0.1 M in supporting electrolyte. Before each measurement, the solutions were 
degassed by bubbling Ar and the working electrode was polished with a polishing machine (Presi 
P230). Under these experimental conditions employed in this work, the half-wave potential (E1/2) 
of the ferrocene Fc+/Fc couple in DMSO was E1/2 = 0.45 V vs SCE. Experimental peak potentials 
have been measured versus SCE and converted to NHE by adding 0.241 V. 
 
4.3. Biology 
4.3.1. Antileishmanial activity against L. donovani promastigotes 
Leishmania species used in this study were L. donovani (MHOM/IN/00/DEVI) purchased from 
CNR Leishmania (Montpellier, France). Leishmania promastigotes forms were grown in 
Schneider’s Drosophila medium (Life Technologies, Saint-Aubin, France) supplemented with 100 
U/mL penicillin, 100 µg/mL streptomycin, 2 mM L-glutamine and 20% FCS (Life Technologies, 
Saint-Aubin, France) at 27 °C. The in vitro evaluation of the antileishmanial activity on 
promastigote forms of the tested compound was carried out by an MTT assay according to the 
Mosmann protocol [29] with some modifications. Briefly, promastigotes in log-phase were 
incubated at an average density of 106 parasites/mL in sterile 96-well plates with various 
concentrations of compound dissolved in DMSO (final concentration less than 0.5% v/v), in 
duplicate. Appropriate controls treated by DMSO, miltefosine, amphotericin B, fexinidazole and 
doxorubicin (reference drugs purchased from Sigma-Aldrich, Saint-Louis, Missouri, USA) were 
added to each set of experiments. After a 72h incubation period at 27 °C, parasitic metabolic 
activity was determined. Each plate-well was then microscope-analyzed for detecting possible 
precipitate formation. 20 µL of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) (Sigma-Aldrich, Saint-Louis, Missouri, USA) solution (5 mg/mL in PBS) were added to 
each well followed and incubated 4 h at 27 °C. The enzyme reaction was then stopped by addition 
of 100 µL of 50% isopropanol – 10% sodium dodecyl sulfate. Plates were shaken vigorously at 
300 rpm for 10 min. The absorbance was finally measured at 570 nm in a BIO-TEK Elx808 
(Biotek, Colmar, France) absorbance microplate reader. Inhibitory concentration 50% (EC50) was 
defined as the concentration of drug required to inhibit by 50% the metabolic activity of 
Leishmanial promastigotes forms compared to the control. EC50 were calculated by non-linear 
regression analysis processed dose-response curves, using TableCurve 2D V5.0 software. EC50 
values represent the mean value calculated from at least three independent experiments. 
 
4.3.2. Antileishmanial activity on L. infantum axenic amastigotes [29] 
L. infantum promastigotes (MHOM/MA/67/ITMAP-263, CNR Leishmania, Montpellier, France, 
expressing luciferase activity) were cultivated in RPMI 1640 medium supplemented with 10% 
foetal calf serum (FCS), 2 mM L-glutamine and antibiotics (100 U/mL penicillin and 100 µg/mL 
streptomycin) and harvested in logarithmic phase of growth by centrifugation at 900 g for 10 min. 
The supernatant was removed carefully and was replaced by the same volume of RPMI 1640 
complete medium at pH 5.4 and incubated for 24 h at 24 °C. The acidified promastigotes were 
then incubated for 24 h at 37 °C in a ventilated flask to transform promastigotes into axenic 
amastigotes. The amastigote stage was checked both by electron microscopy (short flagellum with 
small bulbous tip extending beyond a spherical cell body) and RT-PCR for confirming the 
overexpression of ATG8 and amastin genes in amastigotes, compared to promastigotes.  The 
effects of the tested compounds on the growth of L. infantum axenic amastigotes were assessed as 
follows. L. infantum amastigotes were incubated at a density of 2 × 106 parasites/mL in sterile 96-
well plates with various concentrations of compounds dissolved in DMSO (final concentration 
less than 0.5% v/v), in duplicate. Appropriate controls DMSO, amphotericin B, miltefosine and 
fexinidazole (reference drugs purchased from Sigma Aldrich) were added to each set of 
experiments. After a 48 h incubation period at 37 °C, each plate-well was then microscopically-
examined to detect any precipitate formation. To estimate the luciferase activity of axenic 
amastigotes, 80 µL of each well were transferred to white 96-well plates, Steady Glow® reagent 
(Promega) was added according to manufacturer's instructions, and plates were incubated for 2 
min. The luminescence was measured in Microbeta Luminescence Counter (PerkinElmer). 
Efficient concentration 50% (EC50) was defined as the concentration of drug required to inhibit by 
50% the metabolic activity of L. infantum amastigotes compared to control. EC50 values were 
calculated by non-linear regression analysis processed on dose response curves, using TableCurve 
2D V5 software. EC50 values represent the mean of three independent experiments. 
 
4.3.3. Antileishmanial activity on L. donovani  intracellular amastigotes 
4.3.3.1. Cells culture 
The undifferentiated THP1 (ATCC) human monocyte cells  were grown  in RPMI 1640 medium 
(Life Technologies, Saint-Aubin, France) supplemented with 10% FCS (Life Technologies, Saint-
Aubin, France), 100 U/mL penicillin, 100 µg/mL streptomycin and 2 mM L-glutamine at 37 °C, 
5% CO2. The culture was maintained between 3.10
5 and 1.106 cells/ml. 
4.3.3.2. Antileishmanial evaluation 
The in vitro evaluation of the antileishmanial activity on intracellular amastigotes forms of the 
tested compound was assessed according to the da Luz et al protocol [30] with some modifications. 
Briefly, 400 µL of THP-1 cells with Phorbol 12-Myristate 13-Acetate (final concentration 50 
ng/ml) were seeded in sterile chamber-slides at an average density of 5 × 104 cells/ml and 
incubated for 48 h at 37 °C, 5 µ CO2. Leishmanial promastigotes forms were centrifuged at 3000 
rpm for 10 min and the supernatant replaced by the same volume of Schneider 20% FCS pH 5.4 
and incubated for 24 hours at 27 °C. Differentiated THP-1 cells were then infected by acidified 
promastigotes with an infection ratio of ten parasites for one macrophage and incubated for 24 
hours at 37 °C, 5% CO2. Then, in duplicate, the medium containing various concentrations of 
tested-compounds was added (final DMSO concentration being inferior to 0.5% v/v). Appropriate 
control treated with or without solvent (DMSO), and various concentration of miltefosine, 
Amphotericin B and Fexinidazole (reference drugs purchased from Sigma-Aldrich, Saint-Louis, 
Missouri, USA) were added to each set of experiments. After 120 hours incubation at 37 °C, 5% 
CO2, well supernatant was removed. Cells were then fixed with analytical grade methanol and 
stained with 10% Giemsa (Sigma-Aldrich, Saint-Louis, Missouri, USA). The percentage of 
infected macrophages in each assay was determined microscopically by counting at least 200 cells 
in each sample. IC50 was defined as the concentration of drug necessary to produce 50% decrease 
of infected macrophages compared to the control. IC50 were calculated by non-linear regression 
analysis processed on dose-response curves, using Table-Curve 2D V5.0 software. IC50 values 
represent the mean value calculated from at least three independent experiments. 
 
4.3.4. Antitrypanosomal evaluation on T. b. brucei BSF trypomastigotes 
The effects of the tested compounds on the growth of T. b. brucei were assessed by Alamar Blue® 
assay described by Räz et al. [31] T. b. brucei AnTat 1.9 (IMTA, Antwerpen, Belgium) was 
cultured in MEM with Earle’s salts, supplemented according to the protocol of Baltz et al. [32] 
with the following modifications: 0.5 mM mercaptoethanol (Sigma Aldrich®, France), 1.5 mM L-
cysteine (Sigma Aldrich®), 0.05 mM bathocuproïne sulfate (Sigma Aldrich®) and 20% heat-
inactivated horse serum (Gibco®, France), at 37 °C and 5% CO2. They were incubated at an 
average density of 2000 parasites/100 µL in sterile 96-wells plates (Fisher®, France) with various 
concentrations of compounds dissolved in DMSO, in duplicate. Appropriate controls treated by 
DMSO on sterile water, suramin, eflornithine and fexinidazole (reference drugs purchased from 
Sigma Aldrich, France and Fluorochem, UK) were added to each set of experiments. After a 69 h 
incubation period at 37 °C, 10 µL of the viability marker Alamar Blue® (Fisher, France) was then 
added to each well, and the plates were incubated for 5 h. The plates were read in a ENSPIRE 
microplate reader (PerkinElmer) using an excitation wavelength of 530 nm and an emission 
wavelength of 590 nm. EC50 was defined as the concentration of drug necessary to inhibit by 50% 
the activity of T. b. brucei compared to the control. EC50 were calculated by nonlinear regression 
analysis processed on dose-response curves, using GraphPad Prism software (USA). EC50 values 
were calculated from three independent experiments. 
 
4.3.5. Antitrypanosomal activity on T. brucei NTR1 over-expressing strain. 
Trypanosoma brucei bloodstream-form 'single marker' S427 (T7RPOL TETR NEO) and drug-
resistant cell lines were cultured at 37 °C in HMI9-T medium [33] supplemented with 2.5 μg/mL 
G418 to maintain expression of T7 RNA polymerase and the tetracycline repressor protein. 
Bloodstream trypanosomes overexpressing the T. brucei nitroreductase (NTR1) [34] were grown 
in medium supplemented with 2.5 μg/mL phleomycin and expression of NTR was induced by the 
addition of 1 μg/mL tetracycline. Cultures were initiated with 1 × 105 cells/mL and sub-cultured 
when cell densities approached 1–2 (× 106)/mL. 
In order to examine the effects of inhibitors on the growth of these parasites, triplicate cultures 
containing the inhibitor were seeded at 1 × 105 trypanosomes/mL. Cells overexpressing NTR were 
induced with tetracycline 48 h prior to EC50 analysis. Cell densities were determined after culture 
for 72 h, as previously described [35]. EC50 values were determined using the following two-
parameter equation by non-linear regression using GRAFIT:  
where the experimental data were corrected for background cell density and expressed as a 




















In this equation, [I] represents inhibitor concentration and m is the slope factor. 
 
4.3.6. Cytotoxicity evaluation on HepG2 cell line 
HepG2 cell line was maintained at 37 °C, 6% CO2 with 90% humidity in RPMI supplemented 
with 10% fœtal bovine serum, 1% L-glutamine (200 mM) and penicillin (100 U/mL)/streptomycin 
(100 mg/mL) (complete RPMI medium). The evaluation of the tested molecules cytotoxicity on 
the HepG2 (hepatocarcinoma cell line purchased from ATCC, ref HB-8065) cell line was 
performed according to the method of Mosmann [36] with slight modifications. Briefly, 5 × 103 
cells in 100 mL of complete medium were inoculated into each well of 96-well plates and 
incubated at 37 °C in a humidified 6% CO2. After 24 h incubation, 100 mL of medium with various 
product concentrations dissolved in DMSO (final concentration less than 0.5% v/v) were added 
and the plates were incubated for 72 h at 37 °C. Triplicate assays were performed for each sample. 
Each plate-well was then microscope-examined for detecting possible precipitate formation before 
the medium was aspirated from the wells. 100 mL of MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide) solution (0.5 mg/mL in medium without FCS) were then added 
to each well. Cells were incubated for 2 h at 37 °C. After this time, the MTT solution was removed 
and DMSO (100 mL) was added to dissolve the resulting blue formazan crystals. Plates were 
shaken vigorously (700 rpm) for 10 min. The absorbance was measured at 570 nm with 630 nm 
as reference wavelength using a BIO-TEK ELx808 Absorbance Microplate Reader. DMSO was 
used as blank and doxorubicin (purchased from Sigma Aldrich) as positive control. Cell viability 
was calculated as percentage of control (cells incubated without compound). The 50% cytotoxic 
concentration (CC50) was determined from the dose–response curve by using the TableCurve 2D 
v.5.0 software (Jandel scientific). CC50 values represent the mean value calculated from three 
independent experiments. 
 
4.3.7. Cytotoxicity on THP-1 cell line 
The evaluation of the tested molecules cytotoxicity on the THP-1 cell line (acute monocytic 
leukemia cell line purchased from ATCC, ref TIB-202) was performed according to the method 
of Mosman [36] with slight modifications. Briefly, cells in 100 µL of complete RPMI medium, 
were incubated at an average density of 5 × 104 cells/mL in sterile 96-well plates with various 
concentrations of compounds dissolved in DMSO (final concentration less than 0.5% v/v), in 
duplicate. The plates were incubated for 72 h at 37 °C. Each well plate was then microscope-
examined for detecting possible precipitate formation before the medium was aspirated from the 
wells. 100 µL of MTT solution (0.5 mg/mL in medium without FCS) were then added to each 
well. Cells were incubated for 2 h at 37 °C. After this time, the MTT solution was removed and 
DMSO (100 µL) was added to dissolve the resulting blue formazan crystals. Plates were shaken 
vigorously (300 rpm) for 10 min. The absorbance was measured at 570 nm with 630 nm as 
reference wavelength spectrophotometer using a BIO-TEK ELx808 Absorbance Microplate 
Reader. DMSO was used as blank and doxorubicin (purchased from Sigma Aldrich) as positive 
control. Cell viability was calculated as percentage of control (cells incubated without compound). 
The 50% cytotoxic concentration (CC50) was determined from the dose–response curve by using 
the TableCurve 2D v.5.0 software. CC50 values represent the mean value calculated from three 
independent experiments. 
 
4.3.8.  Plasma protein binding  
Plasma doped with the tested compound is incubated at 37 °C in triplicate in one of the 
compartments of the insert, the other compartment containing a phosphate buffer solution at pH 
7.2. After stirring for 4 h at 300 rpm, a 25 μL aliquot of each compartment is taken and diluted; 
the dilution solution is adapted to obtain an identical matrix for all the compartments after dilution. 
In parallel, the reprocessing of a plasma doped but not incubated will allow to evaluate the recovery 
of the study. The LC-MS used for this study is a Waters® Acquity I-Class / Xevo TQD, equipped 
with a Waters® Acquity BEH C18 column, 50 × 2.1 mm, 1.7 µM. The mobile phases are (A) 
ammonium acetate 10 mM and (B) acetonitrile with 0.1% formic acid. The injection volume is 1 
µL and the flow rate is 600 µL/min. The chromatographic analysis, total duration of 4 min, is made 
with the following gradient: 0 < t < 0.2 min, 2% (B); 0.2 < t < 2 min, linear increase to 98% (B); 
2 < t < 2.5 min, 98% (B); 2.5 < t < 2.6 min, linear decrease to 2% (B); 2.6 < t < 4 min, 2% (B). 
Carbamazepine, oxazepam, warfarin and diclofenac are used as reference drugs and propranolol 




× 100. The percentage of recovery is calculated according to the 
following formula: 
% Recovery =  
(VPBS × APBS,4h) + (VPlasma × APlasma,4h)
(VPlasma × APlasma,0h)
 
Where A is the ratio of the area under peak of the studied molecule and the area under peak of the 
internal standard (propranolol 200 nM). V is the volume of solution present in the compartments 
(VPBS = 350 µL and Vplasma = 200 µL). 
 
4.3.9.  Microsomal stability 
The tested product and propranolol, used as reference, are incubated in duplicate (reaction volume 
of 0.5 mL) with female mouse microsomes (CD-1, 20 mg/mL, BD Gentest™) at 37 °C in a 50 
mM phosphate buffer, pH 7.4, in the presence of MgCl2 (5 mM), NADP (1 mM), glucose-6-
phosphate dehydrogenase (0.4 U/mL) and glucose-6-phosphate (5 mM). For the estimation of the 
intrinsic clearance: 50 µL aliquot at 0, 5, 10, 20, 30 and 40 min are collected and the reaction is 
stopped with 4 volumes of acetonitrile (ACN) containing the internal standard. After 
centrifugation at 10000 g, 10 min, 4 °C, the supernatants are kept at 4 °C for immediate analysis 
or placed at -80 °C in case of postponement of the analysis. Controls (t0 and tfinal) in triplicate are 
prepared by incubation of the internal standard with microsomes denatured by acetonitrile. The 
LC-MS used for this study is a Waters® Acquity I-Class / Xevo TQD, equipped with a Waters® 
Acquity BEH C18 column, 50 × 2.1 mm, 1.7 µm. The mobile phases are (A) ammonium acetate 
10 mM and (B) acetonitrile with 0.1% formic acid. The injection volume is 1 µL and the flow rate 
is 600 µL/min. The chromatographic analysis, total duration of 4 min, is made with the following 
gradient: 0 < t < 0.2 min, 2% (B); 0.2 < t < 2 min, linear increase to 98% (B); 2 < t < 2.5 min, 98% 
(B); 2.5 < t < 2.6 min, linear decrease to 2% (B); 2.6 < t < 4 min, 2% (B). 8-Bromo-6-chloro-3-
nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridine 1c is used as internal standard. The 
quantification of each compound is obtained by converting the average of the ratios of the 
analyte/internal standard surfaces to the percentage of consumed product. The ratio of the control 
at t0 corresponds to 0% of product consumed. The calculation of the half-life (t1/2) of each 





, where k is 
the first-order degradation constant (the slope of the logarithm of compound concentration versus 
incubation time). The intrinsic clearance in vitro (Clint expressed in μL/min/mg) is calculated 





⁄   
Where dose is the initial concentration of product in the sample, AUC∞ is the area under the 
concentration-time curve extrapolated to infinity and [microsomes] is the microsome 
concentration expressed in mg/µL. 
 
4.3.10.  Parallel artificial membrane permeability assay (PAMPA) 
The Pampa-BBB experiments were conducted using the Pampa Explorer Kit (Pion Inc) according 
to manufacturer's protocol. Briefly, the stock compound solution (20 mM in DMSO) was diluted 
in Prisma HT buffer pH 7.4 (pION) to 100 µM. 200 µL of this solution (n = 6) was added to donor 
plate (P/N 110243). 5 µL of the BBB-1 Lipid (P/N 110672) was used to coat the membrane filter 
of the acceptor plate (P/N 110243). 200 µL of the Brain Sink Buffer (P/N 110674) was added to 
each well of the acceptor plate. The sandwich was incubated at room temperature for 4 h, without 
stirring. After the incubation the UV-visible spectra were measured with the microplate reader 
(Tecan infinite M200) and the permeability value (Pe) was calculated by the PAMPA Explorer 
software v.3.7 (pION). Corticosterone (Pe = 130.3 ± 7.1 nm/s), and theophylline (Pe = 4.7 ± 0.6 
nm/s) were used as high and low permeability standards, respectively. Each measure was 
performed in sixplicate. 
 
4.4. Thermodynamic solubility at pH 7.4 of compound 15 
Thermodynamic solubility at pH 7.4 of compounds was determined according to 
a miniaturized shake-flask method (Organisation for Economic Cooperation and Development 
guideline n°105) [37]. Phosphate Buffer solutions (pH 7.4, 10 µM, ionic strength 150 µM) were 
prepared from Na2HPO4, KH2PO4 and KCl (Sigma Aldrich, Saint Quentin Fallavier, France); 10 
µL of 20 mM stock solution were added to 5 mL glass tube containing 990 mL buffer (n = 4). Tubes 
were briefly sonicated and shacked by inversion during 24 h at room temperature. Then, 
tube contents were put in a microtube which was centrifuged at 12,225 g for 10 min; 100 µL 
supernatant was mixed with 100 µL acetonitrile in a Greiner UV microplate. Standard solutions 
were prepared extemporaneously diluting 20 mM DMSO stock solutions at 0, 2 and 5 mM; 5 µL 
each working solution was diluted with 995 µL buffer and 100 µL was then mixed in microplate 
with 100 µL acetonitrile to keep unchanged the final proportions of each solvent in standard 
solutions and samples. Determination of solubility at pH 7.4 was calculated from UV spectra (230 
to 450 nm) obtained using a Synergy 2 (Biotek, Colmar, France) microplate reader. The calibration 
curve was obtained from absorbance measures at 370 nm of the three standard solutions at 0, 10 
and 25 µM in a 50:50 (vol/vol) mixture of buffer with acetonitrinile/DMSO (99:1; 
vol/vol). Calibration curves were linear with R² > 0.99. 
 
4.5. Micronucleus assay method 
Cell line: the micronucleus assay was performed on a Chinese Hamster Ovary cell line CHO-K1 
(ATCC, United States, ATCC® CCL-61, n°6574112, Lot 12516, low passage number (<50).  
Culture medium: McCoy's 5A medium (PAN BIOTECH, Lot 4487521) supplemented with 1 
mM glutamine, 10 µg/mL of a mixture of penicillin-streptomycin (PAN BIOTECH, Lot 784561) 
and 10% of inactivated calf serum (PAN BIOTECH, Lot P114526), pΗ 7.2, freshly prepared, 
stored no longer than 1 week. 
Dilutions of test substances: the test material was dissolved into DMSO. Due to its low solubility 
in the culture medium, the maximal soluble concentration to be tested was 0.5 mM. 
Controls: solvent control: PBS; Positive controls: mitomycin C (0.6 µg/mL) and benzo[a]pyrene 
(5 µg/mL), diluted in DMSO and stored at -80 °C. 
Test procedure: all the assays were conducted in duplicate. The CHO-K1 cells, suspended in Mac 
Coys'5A medium, were transferred into Labteck wells at a concentration of 100,000 cells/ml, and 
incubated for 24 h at 37°C in CO2 (5%). When the test was performed without metabolic 
activation, the test substances were added into cell cultures at concentrations previously defined. 
A negative control containing culture medium, a solvent control containing 1% DMSO and a 
positive control containing 0.6 µg/mL of mitomycin C were added. When the assay was performed 
in the presence of metabolic activation, S9 mix metabolizing mixture was added to cell cultures at 
a concentration of 10%. Then the test substances were added to the cell cultures at concentrations 
previously defined. A negative control containing culture medium, a solvent control containing 
1% DMSO and a positive control containing 5 µg/ml of benzo[a]pyrene were added. After 3 hours 
of incubation at 37 °C in CO2 (5%), the culture medium was removed, the cells were rinsed with 
phosphate buffered saline (PBS), and then returned to culture in McCoy's 5A medium containing 
3 µg/ml of cytochalasin B. After a 21-hour incubation period at 37°C, cells were rinsed with 
phosphate buffered saline (PBS), fixed with methanol and stained with 10% Giemsa for 20 
minutes. 
Analysis of results: the analysis of results was performed under a microscope at ×1000 
magnification. The antiproliferative activity of test substances was estimated by counting the 
number of binucleated cells relative to the number of mononucleated cells on a total of 500 cells 
for each dose (250 cells counted per well). The proliferation index (Cytokinesis Blocked 
Proliferative Index CBPI) was calculated using the following formula: 
CBPI = (2 × 𝐵𝐼 + 𝑀𝑂𝑁𝑂)/500 
BI: number of binucleated cells 
MONO: number of mononucleated cells 
The cytostasis index (CI%), i.e. the percentage of cell replication inhibition, was calculated using 
the following formula: 
CI%: 100 - {100 × (CBPItest material - 1)/(CBPIsolvent control - 1) 
After this step, only the doses inducing a decrease of less than 55 ± 5% of CI% as compared to the 
negative control were taken into account for counting micronuclei. The rates of micronuclei were 
evaluated for the presence of independent nuclear core entities in 1000 binucleated cells per well, 
which corresponds to 2000 cells examined by test substance dose. Micronuclei were identified as 
small nuclei well differentiated from cell nucleus, stained in the same manner and having a 
diameter less than one third of that of the cell nucleus. 
 
Micronuclei rates obtained for different doses of test substances were compared to the negative 
control by a χ2 test. The assay was considered positive if: 
- A dose-response relationship was obtained between the rate of micronuclei and the doses tested, 
- At least one of these doses induced a statistically significant increase (P < 0.05) in the number of 
micronucleated cells as compared to the negative control. 
 
4.6. Comet assay  
4.6.1. Cell culture and treatment 
The human hepatocarcinoma cell line HepG2 was obtained from the American Type Culture 
Collection (ATCC, ref. HB-8065). Cells were cultured in Eagle’s Minimum Essential Medium 
(EMEM, ref. ATCC® 30-2003TM) supplemented with 10% heat-inactivated fetal bovine serum, 
100 U/mL penicillin and 0.1 mg/mL streptomycin (all from Gibco). Cells were maintained at 37 
°C in a humidified atmosphere with 5% CO2. Cells were used in passage number 5-8. 
Compound 8 was tested at 3 concentrations (5, 10 and 20 µM) for 3 different times of incubation 
(2, 24 and 72 h). Briefly, HepG2 cells were seeded at 1.13 x 105 cells/mL in 6-well plates (3 mL 
of cell suspension per well) and incubated at 37 °C in a humidified atmosphere with 5% CO2. After 
24, 72 and 94 h of incubation, cells were treated with different concentrations of the compound or 
the vehicle (0.5% dimethylsulfoxide, DMSO) for 72, 24 and 2 h respectively. Additionally, in the 
2 h treatment plate, cell in an additional well were treated with 1mM methyl methanesulfonate 
(MMS) as positive control for the comet assay.  
After treatment, medium was removed from the wells and cells were washed with phosphate 
buffered saline (PBS). Finally, cells were trypsinized and trypsin was neutralized with fresh 
medium. From this point, cells were kept ice-cold to avoid DNA repair.  
4.6.2. Comet assay 
The standard alkaline comet assay was employed for the detection of DNA strand breaks (SBs) 
and alkali-labile sites (ALS) in cell treated with compound 8. Trypsinized HepG2 cells were 
centrifuged at 125 g for 5 min at 4 °C and resuspended in cold PBS at 1 x 106 cells/mL. For the 
preparation of the agarose gels, 30 μL of cell suspension were mixed with 140 μL of 1 % low 
melting point agarose in PBS at 37 °C and 2 aliquots of 70 µL of cell/agarose mixture were placed 
on agarose-precoated microscope slides. Each droplet was covered with a 20 x 20 mm coverslip 
and after 2-3 min on a cold metal plate the coverslips were removed. Then, slides were immersed 
in lysis solution (2.5 M NaCl, 0.1 M Na2EDTA, 0.01 M Tris base, pH 10 and 1% Triton X-100) 
at 4 °C for 1 h. After lysis, slides were transferred to the electrophoresis tank and incubated for 40 
min at 4 °C in the electrophoresis solution (0.3 M NaOH, 1 mM Na2EDTA, pH > 13) to allow 
DNA unwinding. After that, electrophoresis was carried out at 1.2 V/cm for 20 min (4 °C). Then, 
gels were neutralized and washed by immersing the slides in PBS for 10 min and distilled water 
for another 10 min (both at 4 °C). Gels were then air dried at room temperature.  
Comets were stained by adding 30 µL of 1 μg/mL of 4,6-diamidino-2-phenylindole (DAPI) on top 
of each gel and placing 22 x 22 mm coverslips on top. Slides were incubated with DAPI at room 
temperature for 30 mins before the analysis. The semi-automated image analysis system Comet 
Assay IV (Instem) was used to evaluate 50 comets per gel (100/condition). The percentage of 
DNA in tail was the descriptor used for each comet. 
4.6.3. Statistics 
The median percentage of DNA in tail for 50 comets was calculated for each of the duplicate gels 
in each experiment and the mean of the two medians was then calculated. The mean percentage of 
DNA in tail of 3 independent experiments and the standard deviation (SD) were calculated. 
 
4.7. In vivo analysis 
Female Swiss mice of 8 weeks (weight 30-32 g) are used. Mice were housed and procedures were 
conducted in agreement with european directive 2010/63/EU on animals used for scientific 
purposes applied in France as the 'Décret n°2012-118 du 1er février 2013 relatif à la protection des 
animaux utilisés à des fins scientifiques'. Accordingly, the present project was APAFIS#19730-
2019031215178087 v1 authorized by the 'Ministère de l'Education Nationale, de l'Enseignement 
Supérieur et de la Recherche'. 
The determination of maximal tolerated dose used one group of 4 mice which received an oral 
administration of 8 at 100 mg/kg. 8 was prepared as a suspension comprising 5% Tween 80/ 95% 
carboxymethylcellulose 0.5% in water. 
Observations of side effects were codified. The same protocol was used with repeated dose during 
5 days. 
4.7.1. In vivo pharmacokinetics parameters 
Chemicals: The internal standard (IS), ornidazole, was obtained from Sigma Aldrich. LC-MS 
Optima grade acetonitrile (ACN) and methanol (MeOH), acetic acid and formic acid (FA) were 
purchased from Fisher Scientific. Ready-to-use QuEChERS salts (6 g MgSO4/1.5 g NaCl/1.5 g 
sodium citrate dihydrate/750 mg sodium citrate sesquihydrate) were supplied by VWR. 
Sample preparation: samples were stored at -20 °C until extraction. 200 µL of ACN containing 
ornidazole (internal standard; IS) at a concentration of 62.5 ng/mL were added to 100 µL blood 
samples. The mixture was vortexed during 30 sec. After 10 min, 40 mg of QuEChERS salts were 
added. Samples were briefly vortexed and centrifuged at 16,000 g for 10 min. Ten microliters of 
the upper layer was directly transferred in an injection vial before being diluted (1/10; v/v) in a 0.1 
% formic acid in water. Finally, 5 μL were injected in the LC-MS-MS system. Calibrations 
standards (9 levels, from 5 to 1,000 ng/mL) and quality controls (QC) (10, 75 and 625 ng/mL) 
were obtained by adding appropriate 20 × working standard solutions in blank whole blood. 
LC-MS/MS conditions: the chromatographic system consisted in two Shimadzu LC-30 AD 
pumps (NexeraX2), a CTO 20AC oven, and a SIL-30AC autosampler (Shimadzu, Marne-la-
Vallée, France). Chromatographic separation was performed using a EC-C8 column (Poroshell 
120, 2.1 mm × 75 mm, 2.7 µM; Agilent) at a flow rate of 0.25 mL/min using a gradient of 0.1% 
acetic acid in water (A) and 0.1% acetic acid in MeOH/ACN 50:50 (B) programmed as follows: 
0.0‒0.1, 20% (B); 0.1‒1.0, 20 to 70% (B); 1.0‒4.0, 70% to 100% (B); 4.0‒5.5, 100% (B); 5.5‒6.0, 
100 to 20% (B); and 6.0‒8.0 column equilibration with 20% (B). Oven temperature was set at 60 
°C. 
A Shimadzu 8060 triple quadrupole mass spectrometer was used in the positive electrospray 
ionization mode. The main common parameter settings were as follows: interface voltage, 1.5 kV; 
nebulizing gas flow, 3 L/min; heating gas flow, 10 L/min; interface temperature, 300 °C; 
desolvatation line (DL) temperature, 250 °C; heat block temperature, 400 °C; and drying gas flow, 
10 L/min. All parameters (collision energy, Q1/Q3 pre-bias) were optimized from standard flow 
injection analysis. Dwell time was set at 100 ms per transition. 
Validation procedure for whole blood: validation protocol and the set of acceptance criteria 
were as follows: 
- Linearity: Calibration curve was generated by plotting the peak area ratios (analyte/internal 
standard) vs the expected concentration. Linearity of the calibration curve was evaluated by a 
quadratic regression analysis using a 1/x² weighting. A value greater than 0.99 was expected for 
the coefficient of determination (r2). 
- Precision and accuracy of the method were assessed at lower limit of quantitation (LLOQ; 5 
ng/mL) and at the three quality control concentrations (10, 75 and 625 ng/mL). Precision is 
calculated as the coefficient of variation (CV%) within a single run (intra-assay; n = 5) and 
between different assays (inter-assay; n = 5), and accuracy is the percentage of deviation between 
nominal and found concentration with the established calibration curve. Acceptance criteria were 
intra-assay and inter-assay precision (CV%) and an accuracy (bias) less than 20%. 
- The lower limit of quantification (LLOQ) was estimated to be the minimal concentration with 
accuracy and precision within ± 20%. The lower limit of detection (LLOD) was calculated based 
on a signal-to-noise ratio >3. 
- Extraction recoveries were determined by comparing the LLOQ and the quality controls samples 
(n = 5) with their extracted blank whole blood counterparts spiked at the correct concentration 
after extraction (n = 3). CV% in the extraction recovery had to be less than 20%. 
- The effect of dilution was investigated on samples spiked at MQC and HQC then analyzed after 
1.25-, two- and four-fold dilutions and on samples spiked at 150% of ULOQ (1500 ng/ml) for a 
two-fold dilution. Precision CV and bias were set less than 25% to successfully validate. 
- The absence of carryover was checked by injecting blank samples just after the analysis of the 
most concentrated sample (1,000 ng/mL). 
Pharmacokinetics: the same samples used for the validation were used for the analysis. Monolix 




This work is supported by Aix-Marseille Université, the Université de Toulouse and the CNRS. 
A. Fairlamb and S. Wyllie are supported by funding from the Wellcome Trust (WT105021). C. 
Fersing thanks the Assistance Publique - Hôpitaux de Marseille (AP-HM) for hospital 
appointment. J. Pedron thanks the Université Paul Sabatier and the Conseil Régional Occitanie for 
PhD funding. The authors thank Dr Vincent Remusat for the NMR spectra recording, Dr 
Christophe Chendo and Dr Valérie Monnier for the HRMS analyses. Catherine Piveteau and 
Alexandre Biela from Institut Pasteur de Lille are also acknowledged for their contribution in 
determining in vitro PK parameters. We thank Dr Jean-Baptiste Woillard for the in vivo 
pharmacokinetic analysis and Mr François-Ludovic Sauvage for his help in mass spectrometry 
analysis. Dr. Amaya Azqueta thanks the 'Ramon y Cajal' programme (RYC-2013-14370) of the 
Spanish Government.  
References 
[1] D.H. Molyneux, L. Savioli, D. Engels, Neglected tropical diseases: progress towards 
addressing the chronic pandemic, Lancet Lond. Engl. 389 (2017) 312–325. 
https://doi.org/10.1016/S0140-6736(16)30171-4. 
[2] S.P.S. Rao, M.P. Barrett, G. Dranoff, C.J. Faraday, C.R. Gimpelewicz, A. Hailu, C.L. 
Jones, J.M. Kelly, J.K. Lazdins-Helds, P. Mäser, J. Mengel, J.C. Mottram, C.E. Mowbray, D.L. 
Sacks, P. Scott, G.F. Späth, R.L. Tarleton, J.M. Spector, T.T. Diagana, Drug Discovery for 
Kinetoplastid Diseases: Future Directions, ACS Infect. Dis. 5 (2019) 152–157. 
https://doi.org/10.1021/acsinfecdis.8b00298. 
[3] WHO | 10th meeting of the Strategic and Technical Advisory Group for Neglected Tropical 
Diseases, WHO. (n.d.). http://www.who.int/neglected_diseases/events/tenth_stag/en/ (accessed 
June 4, 2019). 
[4] S. Burza, S.L. Croft, M. Boelaert, Leishmaniasis, Lancet Lond. Engl. 392 (2018) 951–970. 
https://doi.org/10.1016/S0140-6736(18)31204-2. 
[5] J.A. Pérez-Molina, I. Molina, Chagas disease, Lancet Lond. Engl. 391 (2018) 82–94. 
https://doi.org/10.1016/S0140-6736(17)31612-4. 
[6] P. Büscher, G. Cecchi, V. Jamonneau, G. Priotto, Human African trypanosomiasis, Lancet 
Lond. Engl. (2017). https://doi.org/10.1016/S0140-6736(17)31510-6. 
[7] P.G.E. Kennedy, Update on human African trypanosomiasis (sleeping sickness), J. Neurol. 
266 (2019) 2334–2337. https://doi.org/10.1007/s00415-019-09425-7. 
[8] J.R. Franco, G. Cecchi, G. Priotto, M. Paone, A. Diarra, L. Grout, P.P. Simarro, W. Zhao, 
D. Argaw, Monitoring the elimination of human African trypanosomiasis: Update to 2016, PLoS 
Negl. Trop. Dis. 12 (2018) e0006890. https://doi.org/10.1371/journal.pntd.0006890. 
[9] E.A. Dickie, F. Giordani, M.K. Gould, P. Mäser, C. Burri, J.C. Mottram, S.P.S. Rao, M.P. 
Barrett, New Drugs for Human African Trypanosomiasis: A Twenty First Century Success Story, 
Trop. Med. Infect. Dis. 5 (2020). https://doi.org/10.3390/tropicalmed5010029. 
[10] About Sleeping Sickness | DNDi, Drugs Neglected Dis. Initiat. DNDi. (n.d.). 
https://www.dndi.org/diseases-projects/hat/ (accessed April 9, 2019). 
[11] E.D. Deeks, Fexinidazole: First Global Approval, Drugs. 79 (2019) 215–220. 
https://doi.org/10.1007/s40265-019-1051-6. 
[12] S. Patterson, S. Wyllie, Nitro drugs for the treatment of trypanosomatid diseases: past, 
present, and future prospects, Trends Parasitol. 30 (2014) 289–298. 
https://doi.org/10.1016/j.pt.2014.04.003. 
[13] B. S. Hall, C. Bot, S. R. Wilkinson, Nifurtimox Activation by Trypanosomal Type I 
Nitroreductases Generates Cytotoxic Nitrile Metabolites, J. Biol. Chem. 15 (2011) 13088–13095. 
https://doi.org/10.1074/jbc.M111.230847. 
[14] K. Nepali, H. Y. Lee, J-P. Liou, Nitro-Group-Containing Drugs, J. Med. Chem. 62 (2019) 
2851–2893. https://doi.org/10.1021/acs.jmedchem.8b00147. 
[15] C. Castera-Ducros, L. Paloque, P. Verhaeghe, M. Casanova, C. Cantelli, S. Hutter, F. 
Tanguy, M. Laget, V. Remusat, A. Cohen, M.D. Crozet, P. Rathelot, N. Azas, P. Vanelle, 
Targeting the human parasite Leishmania donovani: Discovery of a new promising anti-infectious 
pharmacophore in 3-nitroimidazo[1,2-a]pyridine series, Bioorg. Med. Chem. 21 (2013) 7155–
7164. https://doi.org/10.1016/j.bmc.2013.09.002. 
[16] C. Fersing, L. Basmaciyan, C. Boudot, J. Pedron, S. Hutter, A. Cohen, C. Castera-Ducros, 
N. Primas, M. Laget, M. Casanova, S. Bourgeade-Delmas, M. Piednoel, A. Sournia-Saquet, V. 
Belle Mbou, B. Courtioux, É. Boutet-Robinet, M. Since, R. Milne, S. Wyllie, A.H. Fairlamb, A. 
Valentin, P. Rathelot, P. Verhaeghe, P. Vanelle, N. Azas, Nongenotoxic 3-Nitroimidazo[1,2-
a]pyridines Are NTR1 Substrates That Display Potent in Vitro Antileishmanial Activity, ACS 
Med. Chem. Lett. 10 (2019) 34–39. https://doi.org/10.1021/acsmedchemlett.8b00347. 
[17] C. Fersing, C. Boudot, J. Pedron, S. Hutter, N. Primas, C. Castera-Ducros, S. Bourgeade-
Delmas, A. Sournia-Saquet, A. Moreau, A. Cohen, J.-L. Stigliani, G. Pratviel, M.D. Crozet, S. 
Wyllie, A. Fairlamb, A. Valentin, P. Rathelot, N. Azas, B. Courtioux, P. Verhaeghe, P. Vanelle, 
8-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent 
antitrypanosomatid molecules bioactivated by type 1 nitroreductases, Eur. J. Med. Chem. 157 
(2018) 115–126. https://doi.org/10.1016/j.ejmech.2018.07.064. 
[18] C. Castera, M. D. Crozet, P. Vanelle, An Efficient Synthetic Route to New Imidazo[1,2-
a]pyridines by Cross-Coupling Reactions in Aqueous Medium, HETEROCYCLES. 65 (2005) 
2979–2989. https://doi.org/10.3987/COM-05-10548. 
[19] M.D. Crozet, C. Castera-Ducros, P. Vanelle, An efficient microwave-assisted Suzuki 
cross-coupling reaction of imidazo[1,2-a]pyridines in aqueous medium, Tetrahedron Lett. 47 
(2006) 7061–7065. https://doi.org/10.1016/j.tetlet.2006.07.098. 
[20] L.G. Menchikov, A.V. Vorogushin, O.S. Korneva, O.M. Nefedov, An Effective Method 
for Alcohol Preparation by Hydrolysis of Organohalides in the Presence of Copper and its Salts in 
Aqueous DMSO, Mendeleev Commun. 5 (1995) 223–224. 
https://doi.org/10.1070/MC1995v005n06ABEH000536. 
[21] M.D. Crozet, C. Castera, M. Kaafarani, M.P. Crozet, P. Vanelle, Synthesis of new 6-
halogeno-imidazo[1,2-a]pyridines by SRN1 reactions, Arkivoc. 2003 (2003) 273–282. 
https://doi.org/10.3998/ark.5550190.0004.a26. 
[22] P. Verhaeghe, A. Dumètre, C. Castera-Ducros, S. Hutter, M. Laget, C. Fersing, M. Prieri, 
J. Yzombard, F. Sifredi, S. Rault, P. Rathelot, P. Vanelle, N. Azas, 4-Thiophenoxy-2-
trichloromethyquinazolines display in vitro selective antiplasmodial activity against the human 
malaria parasite Plasmodium falciparum, Bioorg. Med. Chem. Lett. 21 (2011) 6003–6006. 
https://doi.org/10.1016/j.bmcl.2011.06.113. 
[23] C. Kieffer, A. Cohen, P. Verhaeghe, S. Hutter, C. Castera-Ducros, M. Laget, V. Remusat, 
M.K. M’Rabet, S. Rault, P. Rathelot, N. Azas, P. Vanelle, Looking for new antileishmanial 
derivatives in 8-nitroquinolin-2(1H)-one series, Eur. J. Med. Chem. 92 (2015) 282–294. 
https://doi.org/10.1016/j.ejmech.2014.12.056. 
[24] D. Singh, A.M. Deobald, L.R.S. Camargo, G. Tabarelli, O.E.D. Rodrigues, A.L. Braga, An 
Efficient One-Pot Synthesis of Symmetrical Diselenides or Ditellurides from Halides with CuO 
Nanopowder/Se 0 or Te 0 /Base, Org. Lett. 12 (2010) 3288–3291. 
https://doi.org/10.1021/ol100558b. 
[25] J. McCann, N.E. Spingarn, J. Kobori, B.N. Ames, Detection of carcinogens as mutagens: 
bacterial tester strains with R factor plasmids., Proc. Natl. Acad. Sci. 72 (1975) 979–983. 
https://doi.org/10.1073/pnas.72.3.979. 
[26] D. Tweats, B. Bourdin Trunz, E. Torreele, Genotoxicity profile of fexinidazole--a drug 
candidate in clinical development for human African trypanomiasis (sleeping sickness), 
Mutagenesis. 27 (2012) 523–532. https://doi.org/10.1093/mutage/ges015. 
[27] OECD, Test No. 471: Bacterial Reverse Mutation Test, OECD, 1997. 
https://doi.org/10.1787/9789264071247-en. 
[28] T.T. Wager, X. Hou, P.R. Verhoest, A. Villalobos, Moving beyond Rules: The 
Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach 
To Enable Alignment of Druglike Properties, ACS Chem. Neurosci. 1 (2010) 435–449. 
https://doi.org/10.1021/cn100008c. 
[29] C. Zhang, S. Bourgeade Delmas, Á. Fernández Álvarez, A. Valentin, C. Hemmert, H. 
Gornitzka, Synthesis, characterization, and antileishmanial activity of neutral N-heterocyclic 
carbenes gold(I) complexes, Eur. J. Med. Chem. 143 (2018) 1635–1643. 
https://doi.org/10.1016/j.ejmech.2017.10.060. 
[30] R. Inocêncio da Luz, M. Vermeersch, J.-C. Dujardin, P. Cos, L. Maes, In Vitro Sensitivity 
Testing of Leishmania Clinical Field Isolates: Preconditioning of Promastigotes Enhances 
Infectivity for Macrophage Host Cells, Antimicrob. Agents Chemother. 53 (2009) 5197–5203. 
https://doi.org/10.1128/AAC.00866-09. 
[31] B. Räz, M. Iten, Y. Grether-Bühler, R. Kaminsky, R. Brun, The Alamar Blue® assay to 
determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro, 
Acta Trop. 68 (1997) 139–147. https://doi.org/10.1016/S0001-706X(97)00079-X. 
[32] T. Baltz, D. Baltz, C. Giroud, J. Crockett, Cultivation in a semi-defined medium of animal 
infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. 
gambiense., EMBO J. 4 (1985) 1273–1277. https://doi.org/10.1002/j.1460-2075.1985.tb03772.x. 
[33] N. Greig, S. Wyllie, S. Patterson, A.H. Fairlamb, A comparative study of methylglyoxal 
metabolism in trypanosomatids: Methylglyoxal metabolism in trypanosomatids, FEBS J. 276 
(2009) 376–386. https://doi.org/10.1111/j.1742-4658.2008.06788.x. 
[34] S. Wyllie, B.J. Foth, A. Kelner, A.Y. Sokolova, M. Berriman, A.H. Fairlamb, 
Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei, J. Antimicrob. Chemother. 
71 (2016) 625–634. https://doi.org/10.1093/jac/dkv376. 
[35] D.C. Jones, I. Hallyburton, L. Stojanovski, K.D. Read, J.A. Frearson, A.H. Fairlamb, 
Identification of a κ-opioid agonist as a potent and selective lead for drug development against 
human African trypanosomiasis, Biochem. Pharmacol. 80 (2010) 1478–1486. 
https://doi.org/10.1016/j.bcp.2010.07.038. 
[36] T. Mosmann, Rapid colorimetric assay for cellular growth and survival: Application to 
proliferation and cytotoxicity assays, J. Immunol. Methods. 65 (1983) 55–63. 
https://doi.org/10.1016/0022-1759(83)90303-4. 
[37] C. Lecoutey, D. Hedou, T. Freret, P. Giannoni, F. Gaven, M. Since, V. Bouet, C. 
Ballandonne, S. Corvaisier, A. Malzert Freon, S. Mignani, T. Cresteil, M. Boulouard, S. Claeysen, 
C. Rochais, P. Dallemagne, Design of donecopride, a dual serotonin subtype 4 receptor 
agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer’s disease treatment, 
Proc. Natl. Acad. Sci. 111 (2014) E3825–E3830. https://doi.org/10.1073/pnas.1410315111. 
